[go: up one dir, main page]

WO2006073195A1 - Procede de prediction ou de diagnostic du diabete et kit de prediction ou diagnostic du diabete - Google Patents

Procede de prediction ou de diagnostic du diabete et kit de prediction ou diagnostic du diabete Download PDF

Info

Publication number
WO2006073195A1
WO2006073195A1 PCT/JP2006/300115 JP2006300115W WO2006073195A1 WO 2006073195 A1 WO2006073195 A1 WO 2006073195A1 JP 2006300115 W JP2006300115 W JP 2006300115W WO 2006073195 A1 WO2006073195 A1 WO 2006073195A1
Authority
WO
WIPO (PCT)
Prior art keywords
apolipoprotein
substance
protein
diabetes
transthyretin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2006/300115
Other languages
English (en)
Japanese (ja)
Inventor
Toshikazu Yoshikawa
Yuji Naito
Hisashi Arikuni
Satomi Akagiri
Kenichi Mihara
Toshichika Ooki
Tsugihisa Yamaguchi
Syouichi Mafune
Yutaka Takahashi
Yumiko Nakashima
Motohide Aoki
Mari Kobayashi
Eri Kigawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarker Science Co Ltd
Original Assignee
Biomarker Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarker Science Co Ltd filed Critical Biomarker Science Co Ltd
Priority to JP2006550912A priority Critical patent/JPWO2006073195A1/ja
Publication of WO2006073195A1 publication Critical patent/WO2006073195A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • G01N2333/765—Serum albumin, e.g. HSA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Definitions

  • the present invention relates to a method for prior diagnosis and diagnosis of a disease, a method for evaluating a substance, and a method for screening a substance, and more specifically, using the concentration of a marker substance in a body fluid of a subject as an index.
  • Diagnosis of disease to determine the presence or absence of diabetes or risk of future development (preliminary diagnosis), animals that develop diabetes, or animals with high risk of future development, ingest animals with test substances, and body fluids of the animals
  • the method of evaluating a substance that evaluates the effect of improving diabetes or reducing the risk of future onset of the test substance by using the concentration of the marker substance in the test substance, and the effect of improving diabetes or the future using the evaluation method The present invention relates to a screening method for a substance that screens for a substance having an effect of reducing the risk of developing the disease.
  • the present invention relates to a method for diagnosing glucoseuria by measuring the concentration of a marker substance in blood and comparing the value with a healthy value, and a kit for use in diagnosing diabetes.
  • Diabetes is a complex disease caused by hyperglycemia due to insufficient action of insulin. Diabetes is classified into type 1 and type 2. In type 1 diabetes, as a result of inflammation of the islets of Langernos in the spleen, the ability to secrete insulin is reduced or withered, leading to hyperglycemia. On the other hand, type 2 diabetes causes insulin deficiency due to other causes, leading to hyperglycemia. Is. This type 2 diabetes accounts for the majority of Japanese diabetes and is particularly problematic. The pathogenesis of type 2 diabetes is still unclear. It is believed that the disease is triggered mainly by environmental factors, and overeating and obesity are major causes.
  • the amount of insulin secretion in the spleen increases dramatically due to obesity, resulting in fatigue of the spleen and conversely the decrease in insulin secretion, resulting in insufficient insulin action and hyperglycemia.
  • insulin receptors decrease due to increased fat, resulting in insufficient insulin action and hyperglycemia.
  • the excess glucose produced by the insufficiency of insulin is stored as fat and obesity progresses, and diabetes is closely related to obesity in its pathogenesis.
  • type 2 diabetes often has no subjective symptoms at the beginning of the onset. In other words, it is expected that there will be a considerable number of reserves for type 2 diabetes.
  • Patent Document 1 Japanese Unexamined Patent Application Publication No. 2004-163379
  • An object of the present invention is to provide a diagnostic method for determining the presence or absence of diabetes or the risk of future onset, and a method of evaluating the effect of improving diabetes or reducing the risk of future onset of a test substance, And a means for solving the problem of providing a method for screening a substance having an effect of improving diabetes or reducing the risk of developing future disease using the evaluation method
  • the present inventors have developed a new diabetes that is useful for prior diagnosis and early detection for the prevention of diabetes.
  • proteins that are gene products specific to diabetic patients As a result, we found several proteins with statistically significant differences between diabetics and healthy individuals.
  • these proteins were identified, they were identified as transthyretin, apolipoprotein CII, apolipoprotein CIII, and serum albumin and their derivatives (eg, oxides, cystinates, glycosyl derivatives, etc.) .
  • the present inventors show that transthyretin and apolipoprotein cm in blood are higher than those in healthy subjects in diabetic subjects and pre-diabetes groups, and lower values in healthy subjects than in healthy subjects.
  • the present invention has been completed. That is, the gist of the present invention is as follows.
  • the present inventors also prepared various body fluid samples from the stage before the onset of diabetes, which resolves the above problems, to the boundary between onset and non-onset, and the stage of onset.
  • the body fluid sample was comprehensively analyzed by proteomic analysis using a mass spectrometer.
  • proteomic analysis using a mass spectrometer.
  • proteins that are related to the risk of future onset (that is, enabling pre-diagnosis).
  • a system for determining the presence / absence of diabetes or the risk of future onset ie, prior diagnosis
  • a system for evaluating the diabetic improvement effect or the future risk reduction effect of the test substance was constructed using the concentration of the protein in the body fluid of the animal as an index. Furthermore, using this evaluation method, a system was established to screen for substances that have the effect of improving diabetes or reducing the risk of future onset.
  • the present invention has been completed. That is, the gist of the present invention is as follows.
  • the marker substance is selected from the group consisting of transthyretin, transthyretin derivative, apolipoprotein cn, apolipoprotein cn derivative, apolipoprotein cm, apolipoprotein cm derivative and serum albumin and their corresponding protein strength.
  • the above means are mass spectrometer, nuclear magnetic resonance analyzer, X-ray analyzer, SPR, chromatography, immunological means, biochemical means, electrophoresis instrument, chemical analyzer, two-dimensional fluorescence
  • the quantification means includes a determination means for comparing the standard curve with the measurement result to determine whether the marker substance is within a normal value range.
  • the determination means is a computer.
  • the marker substance includes at least one substance selected from the group consisting of transthyretin and transthyretin derivatives, and the transthyretin derivative comprises S-cystinyl transthyretin, S-cystinyl trans Thyretin, Glutathonylated transthyretin, S—S bond-forming transthyretin, Oxidized transthyretin, Formylated transthyretin, Acetylated transthyretin, Phosphorylated transthyretin, Carbohydrate thyretin with sugar chain 2.
  • the system according to item 1 wherein the system is selected from the group consisting of myristylated transthyretin and complex derivatives thereof.
  • At least one phenomenon selected from the group consisting of a decrease in the transthyretin and an increase in the transthyretin derivative is an indicator of developing diabetes or a high risk for the future.
  • At least one phenomenon selected from the group consisting of a decrease in the transthyretin and an increase in the transthyretin derivative is an indicator of the degree of onset of diabetes or a high risk of developing in the future.
  • the transthyretin has the force encoded by the nucleic acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 3, or the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4, or a modified sequence thereof.
  • the system according to item 21, comprising:
  • the transthyretin derivative is positioned at position 10 in the amino acid sequence encoded by the nucleic acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 3, or in the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4, respectively.
  • 28. The system according to item 21, wherein the cysteine of the cysteine or a corresponding cysteine is a derivatized derivative.
  • the factor or the means further recognizes transthyretin and S-cysteine transthyretin, and the system further comprises means for identifying U between transthyretin and S-cystineyltransthyretin.
  • the system according to item 1.
  • the factor or the means recognizes transthyretin and S-cysteyl transthyretin
  • the system recognizes the molecular weight of transthyretin and the molecular weight of S-cystineyl transthyretin, and trans Item 4.
  • At least one phenomenon selected from the group comprising the decrease in the apolipoprotein CII and the variability of the apolipoprotein CII derivative is an indicator of developing diabetes or high risk of developing in the future.
  • a decrease in the apolipoprotein CII and the variability of the apolipoprotein CII derivative are at least one phenomenon selected from the group consisting of indicators of a degree of developing diabetes or a high risk of developing in the future.
  • the apolipoprotein CII has a force encoded by the nucleic acid sequence shown in SEQ ID NO: 5 or SEQ ID NO: 7, or the amino acid sequence shown in SEQ ID NO: 6 or SEQ ID NO: 8, or a modified sequence thereof.
  • the factor or the means has an ability to selectively identify apolipoprotein CII, and the system includes a means for quantifying the apolipoprotein CII.
  • the marker substance includes apolipoprotein cm or an apolipoprotein CIII derivative, and the apolipoprotein cm is apolipoprotein cni,
  • apolipoprotein cm derivative is selected from the group consisting of apolipoprotein cni and apolipoprotein cm force.
  • (39) at least selected from the group consisting of an increase in apolipoprotein cm, an increase in apolipoprotein cni, and an increase in apolipoprotein cm
  • At least one phenomenon selected from the group consisting of the increase in apolipoprotein cm, the increase in apolipoprotein cni, and the increase in apolipoprotein cm is diabetic.
  • the apolipoprotein cm has a force encoded by the nucleic acid sequence shown in SEQ ID NO: 9 or SEQ ID NO: 11, or the amino acid sequence shown in SEQ ID NO: 10 or SEQ ID NO: 12, or they 39.
  • the system according to item 38, wherein the force is also a morphological force lacking the 20 amino acids at the N-terminal, or a modified sequence thereof.
  • the apolipoprotein cm derivative is represented by the force encoded by the nucleic acid sequence shown in SEQ ID NO: 9 or SEQ ID NO: 11 or the amino acid sequence shown in SEQ ID NO: 10 or SEQ ID NO: 12, Each of the 94th and 95th positions or the corresponding threonine derivative with a sugar chain
  • the factor or the means described above is apolipoprotein cm, apolipoprotein CI
  • the system according to 38. (45) The above-mentioned factor or the above means comprises: apolipoprotein cm and apolipoprotein CI
  • the above-mentioned factor or the above means is apolipoprotein cm, apolipoprotein CI
  • the factor or the means recognizes apolipoprotein cm and an apolipoprotein CII I derivative, and the system comprises apolipoprotein cm and apolipoprotein cn
  • the factor or the means recognizes apolipoprotein cm and an apolipoprotein cn I derivative, and the system comprises apolipoprotein cm, apolipoprotein
  • the factor or the means recognizes apolipoprotein cm and an apolipoprotein cn I derivative, and the system comprises apolipoprotein cm and apolipoprotein.
  • Item 38 further comprising means for distinguishing between II and apolipoprotein cm.
  • the serum albumin has the force encoded by the nucleic acid sequence shown in SEQ ID NO: 13 or SEQ ID NO: 15, or the amino acid sequence shown in SEQ ID NO: 14 or SEQ ID NO: 16, or a modified sequence thereof. 52. The system according to 52.
  • Item 60 The method according to Item 60, wherein the concentration of a marker substance in blood is measured, the value is compared with a healthy value, and the group substance of transthyretin, apolipoprotein CIII, and serum albumin is selected as the marker substance.
  • the apolipoprotein CIII is apolipoprotein CIII, apolipoprotein CIII,
  • Apolipoprotein CIII group power is also selected.
  • Diabetes mellitus diagnosis method according to item 66.
  • step (2) a step of detecting diabetes by comparing the concentration of transthyretin in serum or plasma obtained in step (1) with a healthy value;
  • step (3) if diabetes is not detected in step (2), the step of detecting diabetes by comparing the concentration value of apolipoprotein cm in serum or plasma with a healthy value;
  • step (3) the step of detecting diabetes by comparing the concentration of apolipoprotein CIII in serum or plasma with a healthy value
  • (6) a step of detecting diabetes by comparing the serum albumin obtained in step (5) or the serum albumin concentration value with a healthy value;
  • step (6) If diabetes is detected in step (6), the step of detecting diabetes by comparing the apolipoprotein CIII concentration in serum or plasma with a healthy value;
  • step (7) When diabetes is not detected in step (7), the step of detecting diabetes by further comparing the concentration value of apolipoprotein CIII in serum or plasma with a healthy value;
  • the diagnostic method according to item 67 comprising:
  • the concentration of apolipoprotein CIII in serum or plasma is further compared with a healthy value to detect diabetes.
  • Item 72 The method according to Item 68.
  • the concentration of apolipoprotein CIII in serum or plasma is compared with a healthy value to detect diabetes.
  • Item 72 The method according to Item 69.
  • Item 60 The method according to Item 60, wherein the concentration of the marker substance in the blood is measured, the value is compared with a healthy value, and the marker substance is the following (a;) to (e):
  • Item 60 The method according to Item 60, wherein the concentration of the marker substance in the blood is measured and the value is determined.
  • Item 66 to 73 wherein serum or plasma is contacted with a carrier on which a substance having affinity for the marker substance is immobilized, the marker substance is captured, and the concentration of the marker substance is measured.
  • the method of crab is contacted with a carrier on which a substance having affinity for the marker substance is immobilized, the marker substance is captured, and the concentration of the marker substance is measured.
  • Item 2 The system according to Item 1, wherein the antibody is immobilized on a carrier. (79)
  • Item 60 The method according to Item 60, wherein the following marker substances (a) to (n) in the body fluid of the subject:
  • (m) weak cation exchange at pH 4.0 A protein that binds to the body and produces an ion peak with a mass to charge ratio of approximately 12800 when subjected to mass spectrometry;
  • the body fluid or body fluid component is brought into contact with a carrier on which a substance having affinity for the marker substance is immobilized, the marker substance in the body fluid is captured on the carrier, and based on the amount of the captured marker substance.
  • a carrier on which a substance having affinity for the marker substance is immobilized
  • the marker substance in the body fluid is captured on the carrier, and based on the amount of the captured marker substance.
  • Item 84 The method according to Item 84, wherein the marker substance is the following marker substance (a) to (n):
  • (m) weak cation exchange at pH 4.0 A protein that binds to the body and produces an ion peak with a mass to charge ratio of approximately 12800 when subjected to mass spectrometry;
  • a method wherein the protein is at least one protein selected from the group consisting of: (87)
  • the above-mentioned standard value is the value obtained when an animal that has developed diabetes or an animal that has a high risk of developing in the future is ingested with a known substance that does not have an effect of improving diabetes or reducing the risk of developing future disease. 89.
  • test substance is a food material.
  • the body fluid or body fluid component is brought into contact with a carrier on which a substance having affinity for the marker substance is fixed, the marker substance in the body fluid is captured on the carrier, and the amount of the marker substance captured.
  • a carrier on which a substance having affinity for the marker substance is fixed
  • the marker substance in the body fluid is captured on the carrier, and the amount of the marker substance captured.
  • Substance screening characterized in that the test substance is evaluated by the substance evaluation method described in any of items 84 to 92, and a substance having an effect of improving glucoseuria or reducing the risk of developing future disease is screened. Method.
  • Transthyretin, apolipoprotein cm, and serum albumin are known substances and have some known clinical significance. It has become clear for the first time that the present invention can be a marker substance for diabetes. .
  • diabetes diagnosis and pre-diagnosis can be performed more reliably and accurately.
  • diabetes can be diagnosed and pre-diagnosed by a multi-marker system by combining a plurality of marker substances.
  • diabetes can be diagnosed and pre-diagnosed more easily and with high accuracy.
  • composition diagnosis and pre-diagnosis of the disease of the present invention, in addition to the presence or absence of diabetes, the risk of future onset of diabetes is determined (ie, prior diagnosis). can do.
  • the effect of reducing the risk of developing future diabetes can be evaluated.
  • a substance having an effect of improving diabetes in addition to a substance having an effect of improving diabetes, a substance having an effect of reducing the future risk of developing diabetes can be screened.
  • FIG. 1 is a flowchart showing the procedure of an example in which the method for diagnosing diabetes of the present invention is applied to a multimarker system.
  • FIG. 2 is a flowchart showing another example procedure in which the method for diagnosing diabetes of the present invention is applied to a multi-marker system.
  • FIG. 3 Measurement results for the peak with mZz of 13867 are shown.
  • Fig. 3 (a) is a graph plotting peak intensities for diabetics and healthy subjects
  • Fig. 3 (b) is a graph of Fig. 3 (a). Is a graph showing the maximum value, minimum value, median value, and cut-off value
  • Fig. 3 (c) is a graph showing the ROC curve.
  • FIG. 4 The measurement results for the peak with mZz of 8690 are shown.
  • Fig. 4 (b) is a graph plotting the peak intensities for the normal subjects.
  • Figure 4 (c) is a graph showing the ROC curve.
  • FIG. 5 is a photograph showing the result of subjecting the serum of a diabetic patient to two-dimensional electrophoresis.
  • FIG. 6 The measurement results for the peak with mZz of 66216 are shown.
  • Fig. 6 (a) is a graph plotting peak intensities for diabetics and healthy subjects
  • Fig. 6 (b) is the graph of Fig. 6 (a). Is a graph showing the maximum value, minimum value, median value, and cut-off value
  • FIG. 6 (c) is a graph showing the ROC curve.
  • FIG. 7 Box diagram of the ion peak with mass Z charge ratio of 7043 (average value).
  • FIG. 8 is a box diagram for an ion peak with a mass Z charge ratio of 8325 (average value).
  • FIG. 9 is a box diagram of an ion peak with a mass Z charge ratio of 8532 (average value).
  • FIG. 10 is a box diagram of an ion peak with a mass Z charge ratio of 9062 (average value).
  • FIG. 11 is a box diagram of an ion peak with a mass Z charge ratio of 9255 (average value).
  • FIG. 12 is a box diagram of an ion peak with a mass Z charge ratio of 9445 (average value).
  • FIG. 13 is a box diagram of an ion peak with a mass Z charge ratio of 13720 (average value).
  • FIG. 14 is a box diagram of an ion peak having a mass Z charge ratio of 76404 (average value).
  • FIG. 15 is a box diagram of an ion peak with a mass Z charge ratio of 79085 (average value).
  • FIG. 16 is a box diagram of an ion peak with a mass Z charge ratio of 3497 (average value).
  • FIG. 17 is a box diagram of an ion peak with a mass Z charge ratio of 3559 (average value).
  • FIG. 18 is a box diagram of an ion peak with a mass Z charge ratio of 4184 (average value).
  • FIG. 19 is a box diagram of an ion peak with a mass Z charge ratio of 12786 (average value).
  • FIG. 20 This is a box diagram of the ion peak with mass Z charge ratio of 65700 (average value).
  • FIG. 25 shows the tetrameric structure of TTR and the amino acid sequence of the monomer.
  • transthyretin usually has a tetrameric structure, and it is postulated that when it collapses, it becomes diabetic.
  • FIG. 26 shows the three-dimensional structure (top) and secondary structure sequence (bottom) of the human TTR a-domain.
  • FIG. 27 shows a gel photograph of a band identified as rat apolipoprotein CIII and analysis of the band by SELDI-TOF.
  • FIG. 28 shows a gel photograph of a band identified as rat apolipoprotein CIII and analysis of the band by SELDI-TOF.
  • FIG. 29 shows spots on two-dimensional electrophoresis that are considered to be spots of human polypoprotein CIII (0-2).
  • FIG. 30 shows the result of mass spectrometry of each spot in FIG.
  • FIG. 31 shows the SELDI-MS results for each spot.
  • FIG. 32 shows the results of a CM10 study.
  • FIG. 34 shows the results of examination of optimum conditions. From these results, it is clear that the obtained spot is a spot of human polypoprotein CIII (0-2).
  • FIG. 38 shows measured data for MZZ: 13, 863 in diabetic patients.
  • FIG. 39 shows a diabetic rat serum 8.3K (Apo CII) box diagram.
  • FIG. 40 shows the above time-series data.
  • FIG. 41 shows the results of SELDI-MS of the band on the gel.
  • FIG. 42 shows confirmation of the obtained band by Western blot.
  • FIG. 43 shows the enhancement by anti-ApoC2 antibody in chromatographic fractionation.
  • FIG. 44 shows that apolipoprotein CII in humans is also a pre-diagnostic marker. Here, the mass spectrometry result of a healthy person's apolipoprotein CII is shown.
  • FIG. 45 shows that apolipoprotein CII in humans is also a pre-diagnostic marker.
  • the mass spectrometry result of apolipoprotein CII of a diabetic patient is shown.
  • FIG. 46 shows that apolipoprotein CII in humans using another fraction is also a pre-diagnostic marker. Here, the results of the mass analysis of apolipoprotein CII in healthy individuals are shown.
  • FIG. 47 shows that apolipoprotein CII in humans using a different fraction is also a pre-diagnostic marker. Here, the results of mass spectrometry of apolipoprotein CII in diabetic patients are shown.
  • SEQ ID NOs: 1-2 transthyretin human (nucleic acid and amino acid sequences, respectively)
  • SEQ ID NO: 3-4 transthyretin rat (nucleic acid and amino acid sequences, respectively)
  • SEQ ID NOs: 5-6 apolipoprotein cn human (respectively, nucleic acid sequences) And amino acid sequences)
  • SEQ ID NOs: 7-8 Apolipoprotein cn rat (nucleic acid sequence and amino acid sequence, respectively)
  • SEQ ID NOs: 9-10 apolipoprotein cm human (nucleic acid sequence and amino acid sequence, respectively)
  • SEQ ID NO: 11 12 apolipoprotein cm rat (nucleic acid sequence and amino acid sequence, respectively)
  • SEQ ID NO: 13-14 Serum albumin Human (Nucleic acid sequence and amino acid sequence, respectively)
  • SEQ ID NO: 15-16 Serum albumin Rat (Nucleic acid sequence and amino acid sequence, respectively)
  • SEQ ID NO: 17-18 Serum albumin mouse (Nucleic acid sequence and amino acid sequence, respectively) )
  • SEQ ID NO: 19 Serum albumin (Nucleic acid sequence and amino acid sequence, respectively)
  • SEQ ID NO: 21-22 Serum albumin Usagi (Nucleic acid sequence and amino acid sequence, respectively)
  • SEQ ID NOs: 23-24 Serum albumin monkeys (nucleic acid sequence and amino acid sequence, respectively) BEST MODE FOR CARRYING OUT THE INVENTION
  • Examples of technologies related to protein chips include technologies available from Cyphergen.
  • marker substance refers to a substance that serves as an indicator for tracking whether there is a certain condition (eg, a disease such as diabetes)! .
  • marker substances include genes, gene products, metabolites, and enzymes.
  • gene product refers to a protein or mRNA encoded by a gene.
  • gene products not directly related to sugar metabolism ie, proteins not related to sugar metabolism such as insulin
  • proteins not related to sugar metabolism such as insulin
  • transthyretin is also known as prealbumin, and is known as a protein that forms a tetramer composed of homogenous subunits. It is known to form a protein complex with retinol-binding protein (RBP), which binds to thyroxine (T). In rats, the main T transport tongue
  • Transthyretin was isolated and purified by Raz, A. et al., And its primary structure was identified by Kanda et al. (Raz, A. & Goodman DS, (1969), J. Biol. Chem. 224, 3230-3237; Kanda, Y. et al., (1974), J. Biol. Chem., 247, 6796-6805).
  • Kanda et al. Ros, A. & Goodman DS, (1969), J. Biol. Chem. 224, 3230-3237
  • Kanda, Y. et al. (1974), J. Biol. Chem., 247, 6796-6805.
  • the abnormality is associated with Alzheimer's dementia and familial amyloidosis poly-Europe.
  • a representative nucleotide sequence of transthyretin is:
  • amino acid sequence of transthyretin is:
  • polypeptide having activity (a) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4 or a fragment thereof; (b) having one mutation selected from the group consisting of substitution, addition and deletion in the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, and one or more amino acids, and biological A polypeptide having activity;
  • polypeptide having an amino acid sequence with at least 70% identity to any one of the polypeptides of (a) to (d) and having biological activity
  • transthyretin Representative sequences of transthyretin are shown in SEQ ID NO: 1 or SEQ ID NO: 3 (nucleic acid sequence) and SEQ ID NO: 2 or SEQ ID NO: 4 (amino acid sequence).
  • transthyretin is known as, for example, a protein that forms a tetramer, and is a retinol-binding protein (RBP) that is a vitamin A transport protein in blood.
  • RBP retinol-binding protein
  • T thyroxine
  • Transthyretin is a complex protein consisting of four subunits having a molecular weight of about 14,000 and is synthesized in the liver.
  • the clinical significance of transthyretin in the blood is said to reflect the nutritional state and the ability of the liver to synthesize proteins, and is known to show high levels in the recovery phase of nephrotic syndrome and acute hepatitis.
  • transthyretin refers to both a tetrameric complex protein and a subunit alone without any particular distinction.
  • Transthyretin and its derivatives are not limited to humans, rats, and other animals (for example, mammals) and homologs thereof (hereinafter referred to as "corresponding" genes or proteins). Are known. Therefore, in the present specification, transthyretin and a derivative thereof usually refer to transthyretin and a derivative thereof present in general organisms as well as humans and rats unless otherwise specified.
  • transthyretin derivative refers to any inducement of transthyretin. Refers to conductors, especially metabolites in vivo such as post-translational modifications. Representative transthyretin derivative modifications are shown below with mass variation values:
  • transthyretin derivatives include cystine (systemyl), dartathionization, s-S bond formation, oxidation (eg, oxidation of methionine side chain), formylation , Acetylation, phosphorylation, glycosylation, myristylation, and the like, but are not limited thereto.
  • the amount of transthyretin is reduced in a diabetic patient or at a high risk to the subject, and instead a specific derivative of transthyretin (eg, cysteine transthysine).
  • transthyretin eg, cysteine transthysine
  • Retin, Dartathionized transthyretin, S—S bond-formed transthyretin, oxidized transthyretin (eg, transthyretin with methionine side chain acidified), formylated transthyretin, acetylated transthyretin, phosphorylated Transthyretin, sugar-linked lance thyretin, and myristylated transthyretin were found to increase. Therefore, it is possible to diagnose or pre-diagnose a subject with a high risk of diabetes or its risk using the decrease of these transthyretins or the increase of transthyretin derivatives as an index.
  • apolipoprotein or “apolipid protein” means lipid and A protein that binds to form a lipid protein and is roughly classified into A, B, C, D, and E. It is the protein component of the lipoprotein complex, which is a typical component of human plasma milk fat particles (chylomicron), HDL, LDL, and VLDL. Apolipoprotein C — II (sometimes abbreviated as APOC2) is a polypoprotein present in VLDL, HDL and chylomicrons. It is an active factor of lipoprotein lipase. This protein deficiency results in hyperchylomicronemia and hypertriglyceridemia.
  • Apolipoprotein C-III (sometimes abbreviated as APOC3) is an apolipoprotein present in VLDL, HDL, and chylomicron, and is known to suppress many lipases.
  • APOC3 apolipoprotein C-III
  • a representative nucleotide sequence of apolipoprotein CII is:
  • a polynucleotide encoding a variant polypeptide having biological activity
  • amino acid sequence of apolipoprotein CII is:
  • amino acids In the amino acid sequence set forth in SEQ ID NO: 6 or SEQ ID NO: 8, one or more amino acids have one mutation selected from the group consisting of substitution, addition, and deletion, and have biological activity A polypeptide;
  • polypeptide having an amino acid sequence with at least 70% identity to any one of the polypeptides of (a) to (d) and having biological activity
  • apolipoprotein CII is shown in SEQ ID NO: 5 or SEQ ID NO: 7 (nucleic acid sequence) and SEQ ID NO: 6 or SEQ ID NO: 8 (amino acid sequence).
  • Examples of the biological activity of apolipoprotein CII include the ability to constitute VLDL, HDL, and chylomicron.
  • Apolipoprotein CII is a homologue of humans, rats, and other animals (eg, mammals) (hereinafter referred to as “corresponding” gene or protein, etc.). )It has been known. Therefore, in the present specification, unless otherwise specified, apolipoprotein CII usually refers to apolipoprotein CII that exists in human beings, rats and general organisms.
  • Apolipoprotein is produced as a pro-form. When making a more detailed judgment, it is preferable to distinguish between the body and the mature body.
  • a representative nucleotide sequence of apolipoprotein cm is:
  • one or more amino acids are a variant polypeptide having one mutation selected from the group consisting of substitution, addition and deletion ability, or a fragment thereof A polynucleotide encoding a variant polypeptide having biological activity;
  • one or more amino acids in the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 12, one or more amino acids have one mutation selected from the group consisting of substitution, addition and deletion, and have biological activity Having a polypeptide;
  • polypeptide that is a species homologue of the amino acid sequence set forth in SEQ ID NO: 10 or SEQ ID NO: 12, or (e) a polypeptide having an amino acid sequence with at least 70% identity to any one of the polypeptides of (a) to (d) and having biological activity,
  • apolipoprotein cm Representative sequences of apolipoprotein cm are shown in SEQ ID NO: 9 or SEQ ID NO: 11 (nucleic acid sequence) and SEQ ID NO: 10 or SEQ ID NO: 12 (amino acid sequence).
  • Examples of the biological activity of apolipoprotein CIII include the ability to form VLDL, HDL, and chylomicron.
  • Apolipoprotein cm is the homologue of humans, rats, other animals (eg, mammals) (hereinafter referred to as “corresponding” gene or protein, etc.). )It has been known. Therefore, in the present specification, apolipoprotein cm usually refers to apolipoprotein CIII present in humans, rats, and organisms unless otherwise specified.
  • apolipoprotein cm is at least CIII, CIII, CIII.
  • apolipoprotein CIII is a general term for three types of proteins, and is classified into apolipoprotein cni, apolipoprotein cm, and apolipoprotein cm.
  • the concentration of at least one of these three types of apolipoprotein cm is measured. According to the method for diagnosing diabetes of the present invention, since the concentration of apolipoprotein cm is subdivided and measured, the accuracy is high!
  • Apolipoprotein cm is one of 10 or more apolipoproteins present in the blood and is synthesized in the liver.
  • the clinical significance of apolipoprotein cm in the blood is known to be high in obstructive jaundice antilipidemia.
  • apolipoprotein cm depends on the presence or absence of sugar chains and the difference in structure.
  • Apolipoprotein cni has no sugar chain
  • apolipoprotein cni is apolipoprotein C
  • apolipoprotein cm is apolipoprotein
  • a sugar chain is added to I in a more complex manner.
  • serum albumin means that albumin contained in serum is the most abundant in serum protein (about 4 g per 100 ml), and 60% of the total protein is contained. Occupy. In humans, it has a molecular weight of 64000-68000 and an isoelectric point of pH 4.7-4.9. It has several roles, such as maintaining blood osmotic pressure, binding and transporting various substances (ions, pigments, some water-soluble vitamins, drugs, etc.), and providing a source of amino acids to tissues. It is. Serum albumin is an albumin and the most abundant protein in serum.
  • Serum albumin is a protein that does not have a sugar chain and has a molecular weight of about 69000 (calculated value of amino acid primary structure is 66439) and is synthesized in the liver.
  • the clinical significance of serum albumin in blood is known to be low, reflecting the deterioration of nutritional status and the degree of liver damage.
  • a representative nucleotide sequence of serum albumin is:
  • one or more amino acids are a variant polypeptide or a fragment thereof having one mutation selected from the group consisting of substitution, addition and deletion ability
  • one or more amino acids in the amino acid sequence shown in SEQ ID NO: 14 or SEQ ID NO: 16, one or more amino acids have one mutation selected from the group consisting of substitution, addition and deletion, and have biological activity Having a polypeptide;
  • polypeptides of (a) to (d) and having biological activity (d) a polypeptide that is a species homologue of the amino acid sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 16; or (e) a polypeptide having an amino acid sequence with at least 70% identity to any one of the polypeptides of (a) to (d) and having biological activity,
  • serum albumin Representative sequences of serum albumin are shown in SEQ ID NO: 13 or SEQ ID NO: 15 (nucleic acid sequence) and SEQ ID NO: 14 or SEQ ID NO: 16 (amino acid sequence).
  • the biological activity of serum albumin includes, for example, maintaining blood osmotic pressure, binding and transporting various substances (ions, dyes, some water-soluble vitamins, drugs, etc.), The ability to supply amino acids can be mentioned.
  • Serum albumin is known to be homologous in humans, rats, and other animals (eg, mammals) (referred to herein as “corresponding” genes or proteins). Being! / Therefore, in the present specification, serum albumin usually refers to serum albumin present not only in humans, rats but also in general organisms, unless otherwise specified. Other animal sequences for serum albumin include mouse (SEQ ID NO: 17-18), Inu (SEQ ID NO: 19-20), Usagi (SEQ ID NO: 21-22), monkey (SEQ ID NO: 23-24). it can.
  • diagnosis or pre-diagnosis can be realized by using a factor or means specific to the marker substance.
  • agent refers to any substance or other element (eg, energy such as light, radioactivity, heat, electricity, etc.) as long as the intended purpose can be achieved. There may be.
  • substances include, for example, proteins, polypeptides, oligopeptides, peptides, polynucleotides, oligonucleotides, nucleotides, nucleic acids (eg, DNA such as cDNA, genomic DNA, RNA such as mRNA), Polysaccharides, oligosaccharides, lipids, small organic molecules (e.g.
  • a specific factor for a polynucleotide is typically a polynucleotide having a certain sequence homology to the polynucleotide sequence (for example, 70% or more sequence identity) and complementarity.
  • a transcription factor that binds to the promoter region examples include, but are not limited to, polypeptides such as children.
  • Factors specific for a polypeptide typically include an antibody specifically directed against the polypeptide or a derivative or analog thereof (eg, a single chain antibody), a polypeptide thereof. Examples include, but are not limited to, a specific ligand or receptor when the peptide is a receptor or a ligand, and a substrate when the polypeptide is an enzyme.
  • a factor that specifically interacts” with a biological agent such as a polynucleotide or a polypeptide means an affinity for a biological agent such as that polynucleotide or its polypeptide.
  • Gender is typically the same, or preferably significantly (eg, statistically) greater than its affinity for other unrelated (especially less than 30% identity) polynucleotides or polypeptides. Includes those that are scientifically significant).
  • affinity can be measured, for example, by hybridization assay, binding assay, or the like.
  • a first substance or factor "specifically interacts" with a second substance or factor means that the first substance or factor is to interact with a higher affinity than a substance or factor other than a second substance or factor (especially another substance or factor present in a sample containing a second substance or factor).
  • Specific interactions for substances or factors include both nucleic acids and proteins, such as hybridization in nucleic acids, antigen-antibody reactions in proteins, ligand-receptor reactions, enzyme-substrate reactions, etc. Examples include, but are not limited to, protein-lipid interaction, nucleic acid-lipid interaction, and the like, such as a reaction between a transcription factor and a binding site of the transcription factor.
  • the first substance or factor when both a substance or factor is a nucleic acid, the first substance or factor is “specifically interacting” with the second substance or factor if the first substance or factor is the second substance. Alternatively, it includes at least a part of the complementarity to the factor.
  • the fact that the first substance or factor “specifically interacts” with the second substance or factor includes, for example, an antigen-antibody reaction interaction, Examples include interaction by septa-one ligand reaction, enzyme-substrate interaction, etc. It is not limited to them.
  • the first substance or factor “specifically interacts” with the second substance or factor means that the transcription factor and the transcription factor Interactions with the binding region of the nucleic acid molecule of interest are included.
  • antibody refers to polyclonal antibodies, monoclonal antibodies, multispecific antibodies, chimeric antibodies, and anti-idiotype antibodies, and fragments thereof, such as F (ab ') and Fab fragments, As well as other recombinantly produced conjugates.
  • antibodies may be covalently linked or recombinantly fused to an enzyme, such as alkaline phosphatase, horse radish peroxidase, alpha galactosidase, etc.
  • an enzyme such as alkaline phosphatase, horse radish peroxidase, alpha galactosidase, etc.
  • antigen refers to any substrate that can be specifically bound by an antibody molecule.
  • immunogen refers to an antigen capable of initiating lymphocyte activity that produces an antigen-specific immune response.
  • the antibody used in the present invention may be a polyclonal antibody or a monoclonal antibody.
  • compound means any identifiable chemical entity or molecule, including small molecules, peptides, proteins, sugars, nucleotides, or nucleic acids. Without being limited thereto, and such compounds can be natural or synthetic.
  • small organic molecule means an organic molecule having a relatively small molecular weight. Usually, a small organic molecule has a molecular weight of about 1000 or less, but may have a higher molecular weight. Small organic molecules can be synthesized by using methods known in the art or by combining them. Such small organic molecules may be produced by living organisms. Examples of small organic molecules include hormones, ligands, signal transmitters, Examples include, but are not limited to, small molecules, molecules synthesized by combinatorial chemistry, and small molecules that can be used as pharmaceuticals (for example, small molecule ligands).
  • ligand refers to a substance that specifically binds to a protein.
  • ligands For example, lectins, antigens, antibodies, hormones, neurotransmitters, etc. that specifically bind to various receptor protein molecules present on the cell membrane can be mentioned as ligands.
  • protein protein
  • polypeptide oligopeptide
  • peptide refers to a polymer of amino acids of any length.
  • the polymer may be linear or branched or cyclic.
  • the amino acid may be a modified amino acid, whether natural or non-natural.
  • the term can also refer to a complex assembled into a complex of multiple polypeptide chains.
  • the term also encompasses natural or artificially modified amino acid polymers. Such modifications include, for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphate or any other manipulation or modification (eg, conjugation with a labeling component) and the like. .
  • polypeptides containing one or more analogs of amino acids eg, including non-natural amino acids, etc.
  • peptidomimetic compounds eg, peptoids
  • Other modifications are included.
  • the “polypeptide” of the present invention may refer to a marker substance.
  • amino acid may be natural or non-natural.
  • “Derivative amino acid” or “amino acid analog” refers to an amino acid that is different from a naturally occurring amino acid but has the same function as the original amino acid. Such derivative amino acids and amino acid analogs are well known in the art.
  • natural amino acid means the L isomer of a natural amino acid. Natural amino acids are glycine, alanine, norin, leucine, isoleucine, serine, methionine, threonine, phenylalanine, tyrosine, tryptophan, cysteine, proline, histidine, aspartic acid, asparagine, glutamic acid, glutamine, ⁇ -carboxyglutamic acid Arginine, orthine, and lysine. Unless otherwise indicated, in this specification, all amino acids are in the L form.
  • unnatural amino acid is not normally found in proteins normally. Means an amino acid.
  • non-natural amino acids include the above-mentioned D-form amino acids, norleucine, normal nitrophenylalanine, homophenylalanine, parafluorophenylalanine, 3 amino-2 benzylpropionic acid, homoarginine D-form or L-form and D-phenol- Lualanin is mentioned.
  • amino acid analog refers to a molecule that is not an amino acid but is similar to the physical properties and Z or function of an amino acid.
  • amino acid analogs include ethionine, canavanine, 2-methylglutamine and the like.
  • Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
  • Amino acids may be referred to herein by either their commonly known three letter symbol power or by the one letter symbol recommended by the IUPAC — IUB Biochemica 1 Nomenclature Commission. Nucleotides can also be referred to by the generally accepted single letter code.
  • polynucleotide refers to a polymer of nucleotides of any length.
  • the term also includes “oligonucleotide derivatives” or “polynucleotide derivatives”.
  • Oligonucleotide derivatives refer to oligonucleotides or polynucleotides that include derivatives of nucleotides or that have unusual linkages between nucleotides, and are used interchangeably.
  • oligonucleotides include, for example, 2, 1 O-methyl-ribonucleotide, oligonucleotide derivatives in which a phosphodiester bond in an oligonucleotide is converted to a phosphoroate bond, and oligonucleotides.
  • nucleic acid sequence may also contain conservatively modified variants (eg, degenerate codon substitutes) and complements, as well as explicitly indicated sequences. It is contemplated to encompass the sequence.
  • a degenerate codon substitute creates a sequence in which the third position of one or more selected (or all) codons is replaced with a mixed base and a Z or deoxyinosine residue.
  • nucleotide may be natural or non-natural.
  • Nucleotide derivative or “nucleotide analog” refers to a substance that is different from a naturally occurring nucleotide but has the same function as the original nucleotide.
  • nucleotide derivatives and nucleotide analogs are well known in the art. Examples of such nucleotide derivatives and nucleotide analogs include phosphoroates, phosphoramidates, methylphosphonates, chiral methylphosphonates, 2,1 O-methylribonucleotides, peptide-type nucleic acids (PNA) Not.
  • PNA peptide-type nucleic acids
  • complex molecule refers to a molecule formed by linking a plurality of molecules such as polypeptides, polynucleotides, lipids, sugars, and small molecules.
  • complex molecules include, but are not limited to, glycolipids and glycopeptides.
  • a polypeptide having the amino acid of SEQ ID NO: 2, or a variant or fragment thereof, as long as it has biological activity involved in diagnosis encodes each variant or fragment.
  • Nucleic acid molecules can also be used.
  • a complex molecule containing such a nuclear acid molecule can also be used.
  • nucleic acid is also used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.
  • Particular nucleic acid sequences also include “splice variants”.
  • a particular protein encoded by a nucleic acid has its nucleus Any protein encoded by an acid splice variant is implicitly included.
  • splice variants are the product of alternative splicing of genes. After transcription, the initial nucleic acid transcript can be spliced such that different (alternate) nucleic acid splice products encode different polypeptides.
  • the mechanism of splice variant production varies, but includes exon alternative splicing.
  • Other polypeptides derived from the same nucleic acid by read-through transcription are also included in this definition. Any product of a splicing reaction (including recombinant forms of the splice product) is included in this definition.
  • gene refers to a factor that defines a genetic trait. Usually arranged on a chromosome in a certain order. A gene that defines the primary structure of a protein is called a structural gene, and a gene that affects its expression is called a regulatory gene. As used herein, “gene” may refer to “polynucleotide”, “oligonucleotide” and “nucleic acid” and Z or “protein” “polypeptide”, “oligopeptide” and “peptide”.
  • homology of a gene refers to the degree of identity of two or more gene sequences with respect to each other. Therefore, the higher the homology between two genes, the higher the sequence identity or similarity.
  • the ability of two genes to have homology can be determined by direct sequence comparison or, in the case of nucleic acids, hybridization methods under stringent conditions.
  • the DNA sequence power between the gene sequences is typically at least 50% identical, preferably at least 70% identical, more preferably at least 80%, 90%, If they are 95%, 96%, 97%, 98% or 99% identical, the genes have homology.
  • BLAST is a tool for sequence analysis, using default parameters.
  • An identity search can be performed, for example, using NCBI's BLAST 2.2.9 (issued May 12, 2004).
  • the identity value usually refers to the value when aligned using the above-mentioned BLAST under the default conditions. However, if a higher value is obtained by changing the parameter, the highest value is the identity value. When identity is evaluated in multiple areas, the highest value is used as the identity value.
  • a "corresponding" amino acid or nucleic acid refers to a polypeptide molecule or Refers to an amino acid or nucleotide that has, or is predicted to have, the same effect as a given amino acid or nucleotide in a polypeptide or polynucleotide used as a reference for comparison in a polynucleotide molecule.
  • an antisense molecule can be a similar part in an ortholog corresponding to a particular part of the antisense molecule.
  • the corresponding amino acid is, for example, cystine
  • corresponding amino acid can be the amino acid responsible for the dimer.
  • Such “corresponding” amino acids or nucleic acids may be regions or domains spanning a range. Thus, in such cases, it is referred to herein as a “corresponding” region or domain.
  • a "corresponding" gene eg, a polypeptide molecule or a polynucleotide molecule
  • a gene that is predicted to have for example, a polypeptide molecule or a polynucleotide molecule
  • the gene corresponding to a gene can be an ortholog of that gene.
  • mouse and rat apolipoprotein cn, apolipoprotein cm, transthyretin and serum albumin can find the corresponding apolipoprotein cn, apolipoprotein cm, transthyretin and serum albumin in humans, respectively. .
  • corresponding genes can be identified using techniques well known in the field.
  • the corresponding gene in a certain animal eg, mouse
  • the sequence of the gene that is the basis for the corresponding gene (eg, apolipoprotein cn, apolipoprotein cm, transthyretin, serum albumin).
  • the sequence database of the animal eg, human, rat
  • a “fragment” refers to a polypeptide or polynucleotide having a sequence length of 1 to n ⁇ 1 with respect to a full-length polypeptide or polynucleotide (length n). Say Chido.
  • the length of the fragment can be changed as appropriate according to its purpose. For example, the lower limit of the length is 3, 4, 5, 6, 7, 8, 9, 10 in the case of a polypeptide. , 15, 20, 25, 30, 40, 50 and more amino acids, and lengths expressed in integers not specifically listed here (e.g., 11 etc.) are also suitable as lower limits. It can be.
  • examples include 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100 and more nucleotides.
  • !!, NA! /, Integer lengths (eg 11) may also be appropriate as lower bounds.
  • it is understood that such a fragment falls within the scope of the present invention as long as the full-length fragment functions as a marker as long as the fragment itself also functions as a marker.
  • contacting refers to bringing a compound in physical proximity to the polypeptide or polynucleotide of the present invention, either directly or indirectly. Means that.
  • the polypeptide or polynucleotide can be present in many buffers, salts, solutions, and the like. Contact includes placing the compound in, for example, a beaker, microtiter plate, cell culture flask or microarray (eg, gene chip) containing a polypeptide encoding a nucleic acid molecule or fragment thereof.
  • polynucleotide that is neutralized under stringent conditions refers to well-known conditions commonly used in the art.
  • a colony 'hybridization method plaque' hybridization method, Southern blot hybridization method or the like using a polynucleotide selected from among the polynucleotides of the present invention as a probe.
  • Such a polynucleotide can be obtained. Specifically, using a filter on which colony or plaque-derived DNA is immobilized, 0.7 to 1.
  • a sequence containing only the A sequence or only the T sequence is preferably excluded from the sequence that hybridizes under stringent conditions. Therefore, a polypeptide (for example, transthyretin) used in the present invention includes a nucleic acid that is hybridized under stringent conditions with respect to a nucleic acid molecule encoding a polypeptide particularly described in the present invention. Also included are polypeptides encoded by the molecule.
  • a polynucleotide that can be hybridized refers to a polynucleotide that can hybridize to another polynucleotide under the above hybridization conditions.
  • a polynucleotide capable of hybridizing is a polynucleotide having at least 60% homology with a DNA base sequence encoding a polypeptide having the amino acid sequence represented by SEQ ID NO: 2, 4, 6, etc.
  • a polynucleotide having a homology of 80% or more is preferable, and a polynucleotide having a homology of 95% or more is more preferable.
  • Factors affecting the stability of DNA duplex include base composition, length, and degree of base pair mismatch. Hybridization conditions can be adjusted by those skilled in the art to apply these variables and allow different sequence related DNAs to form hybrids.
  • the melting temperature of a perfectly matched DNA duplex can be estimated by the following equation:
  • N is the length of the double chain formed
  • [Na +] is the molar concentration of sodium ions in the noble, hybridization solution or wash solution
  • % G + C is The percentage of (guanine + cytosine) bases in the.
  • the melting temperature decreases by about 1 ° C for each 1% mismatch.
  • a "purified" biological agent eg, nucleic acid or protein
  • a purified biological agent is one from which at least some of the factors that naturally accompany the biological agent have been removed. Say. Therefore, usually in the purified biological factor of that biological factor Purity is higher (ie, concentrated) than the biological agent is normally present.
  • purified is preferably at least 75 wt%, more preferably at least 85 wt%, even more preferably at least 95 wt%, and most preferably at least 98 wt%. % Of the same type of biological agent is present.
  • expression of a gene, polynucleotide, polypeptide, etc. means that the gene or the like is subjected to a certain action in vivo to take another form. Preferably, it refers to force transcription and translation of genes, polynucleotides, and the like to form a polypeptide, but transcription and production of mRNA may also be an embodiment of expression. More preferably, such polypeptide forms may be post-translationally processed (derivatives herein).
  • detection or “quantification” of polypeptide expression can be accomplished using suitable methods, including, for example, mRNA measurement and immunoassay methods.
  • molecular biological measurement methods include Northern plot method, dot plot method, and PCR method.
  • immunological measurement method include an ELISA method using a microtiter plate, an RIA method, a fluorescent antibody method, a Western plot method, and an immunohistochemical staining method.
  • quantification methods include ELISA and RIA.
  • expression level refers to the amount by which a polypeptide or mRNA is expressed in a target cell or the like. Such expression level is evaluated by any appropriate method including immunological measurement methods such as ELI SA method, RIA method, fluorescent antibody method, Western plot method, and immunohistochemical staining method using the antibody of the present invention. Expressed in the protein level of the polypeptide of the present invention, or used in the present invention evaluated by any appropriate method including molecular biological measurement methods such as Northern blotting, dot blotting, and PCR. Expression level of the polypeptide at the mRNA level.
  • “Change in expression level” means expression at the protein level or mRNA level of the polypeptide used in the present invention evaluated by any appropriate method including the above immunological measurement method or molecular biological measurement method. Means that the amount increases or decreases.
  • the term "binding” refers to a physical or chemical interaction between two proteins or compounds or related proteins or compounds, or a combination thereof. Means. Bonds include ionic bonds, non-ionic bonds, hydrogen bonds, van der Waals bonds, hydrophobic interactions, and the like. A physical interaction (binding) can be direct or indirect, where indirect is due to or due to the effect of another protein or compound. Direct binding refers to an interaction that does not occur through or due to the effects of another protein or compound and is not accompanied by other substantial chemical intermediates.
  • modulate refers to an increase, decrease or maintenance in the amount, quality or effect of a particular activity, transcript or protein. means.
  • “decrease” or “suppression” or synonyms for activity, expression product (eg, protein, transcript (such as RNA)) or the like is a quantity, quality or quantity of a particular activity, transcript or protein or Refers to a decrease in effect or an activity that decreases.
  • the term "probe” refers to a substance used as a search means used in biological experiments such as screening in vitro and Z or in vivo. Examples thereof include, but are not limited to, a nucleic acid molecule containing a specific base sequence or a peptide containing a specific amino acid sequence. In this specification, a probe is used as a marker detection means.
  • Nucleic acid sequences used as probes include nucleic acid sequences that are at least 70% homologous, more preferably at least 80% homologous, more preferably at least 90% homologous, at least 95% homologous to the sequences described above. Is included.
  • search refers to other nucleobase sequences having a specific function and Z or property using a certain nucleobase sequence electronically or biologically or by other methods.
  • Electronic searches include BLAST (Altschul et al., J. Mol. Biol. 215: 403—410 (1990)), FASTA (Pearson & Lipman, Proc. Natl. Acad. Sci., USA 85: 2444- 2448 (1988)), Smith and Waterman method (Smith and Waterman, J. Mol. Biol. 147: 195—197 (1981)), and Needleman and Wunsch method (Needleman and Wunsch, J. Mol. Biol.
  • Bio searches include stringent hybridization, macroarrays with genomic DNA attached to nylon membranes or microarrays (microarray assembly) attached to glass plates, PCR and in situ hybridizers. Examples include, but are not limited to. In the present specification, it is intended that the gene used in the present invention should include the corresponding gene identified by such an electronic search or biological search.
  • the “primer” refers to a substance necessary for the initiation of a reaction of a polymer compound to be synthesized in a polymer synthase reaction.
  • a nucleic acid molecule for example, DNA or RNA
  • the primer can be used as a marker detection means.
  • nucleic acid molecules that are usually used as primers include those having a nucleic acid sequence of at least 8 consecutive nucleotides that is complementary to the nucleic acid sequence of the target gene. It is. Such a nucleic acid sequence is preferably at least 12 contiguous nucleotides of at least 9 contiguous nucleotides, more preferably of at least 10 contiguous nucleotides, more preferably of at least 11 contiguous nucleotides.
  • Nucleic acid sequences used as probes are at least 70% homologous, more preferably at least 80% homologous, more preferably at least 90% homologous, at least 95% homologous to the sequences described above. Nucleic acid sequences are included.
  • a sequence suitable as a primer may vary depending on the nature of the sequence intended for synthesis (amplification), but those skilled in the art can appropriately design a primer according to the intended sequence. Such primer design is well known in the art and may be performed manually or using a computer program (eg, LASERGENE, PrimerSelect, DNAStar).
  • biological activity refers to an activity that a certain factor (for example, a polypeptide or a protein) can have in a living body, and an activity that exhibits various functions. Is included. For example, if an agent is a ligand, its biological activity includes the activity of that ligand binding to the corresponding receptor.
  • transthyretin When detecting transthyretin, transthyretin derivatives, apolipoprotein cn, apolipoprotein cn derivative, apolipoprotein cm, apolipoprotein cin derivative and serum albumin and serum albumin and their corresponding proteins contained in body fluids, etc.
  • transthyretin antibody transthyretin derivative antibody, transthyretin derivative antibody, apolipoprotein cn antibody, Apolipoprotein cn derivative antibody, apolipoprotein cm antibody, apolipoprotein cm derivative antibody and serum albumin antibody and their corresponding protein antibodies.
  • transthyretin antibody transthyretin derivative antibody, apolipoprotein cn antibody, Apolipoprotein cn derivative antibody, apolipoprotein cm antibody, apolipoprotein cm derivative antibody and serum albumin antibody and their corresponding protein antibodies.
  • Such an antibody can be prepared using a conventionally known method.
  • the antibody may be a monoclonal antibody or a polyclonal antibody.
  • transthyretin for example, transthyretin, transthyretin derivatives, apolipoprotein cn, apolipoprotein cn derivative, apolipotan cni, apolipoprotein cm derivative and serum albumin and their corresponding proteins
  • antibodies can be made.
  • Transthyretin monoclonal antibody is prepared by preparing hyperpridoma by cell fusion of antibody-producing cells obtained from animal immunized with an antigen and myeloma cells, and the activity of transthyretin is specifically determined from the resulting hyperidoma. It can be prepared by selecting clones that produce antibodies to inhibit.
  • transthyretin protein used as an antigen for animal immunization examples include all or part of the amino acid sequence of the transthyretin protein prepared by recombinant DNA method or chemical synthesis.
  • transthyretin monoclonal antibody for specifically detecting the transthyretin protein present on the cell surface any 10 or more peptides in the amino acid sequence of the transthyretin protein shown in SEQ ID NO: 2 can be used. Is preferably used as an antigen.
  • transthyretin e.g., transthyretin, transthyretin derivatives, apolipoprotein cn, apolipoprotein cn derivatives, apolipoprotein cm, apolipoprotein cm derivatives and serum albumin and their corresponding Antigens
  • transthyretin e.g., transthyretin, transthyretin derivatives, apolipoprotein cn, apolipoprotein cn derivatives, apolipoprotein cm, apolipoprotein cm derivatives and serum albumin and their corresponding Antigens
  • transthyretin e.g., transthyretin, transthyretin derivatives, apolipoprotein cn, apolipoprotein cn derivatives, apolipoprotein cm, apolipoprotein cm derivatives and serum albumin and their corresponding Antigens
  • proteins such as proteins.
  • transthyretin for antigen is bound to a carrier protein (for example, thyroglobulin).
  • a carrier protein for example, thyroglobulin
  • an adjuvant is added.
  • Freund's complete And incomplete adjuvant of Freund and Freund, etc., and any of these may be mixed.
  • the antigen obtained as described above is administered to mammals such as mammals such as mice, rats, horses, monkeys, rabbits, goats, and hidges.
  • Immunization can be performed by any existing method, but is mainly performed by intravenous injection, subcutaneous injection, intraperitoneal injection, or the like. Immunization intervals are not particularly limited, and immunization is performed at intervals of several days to several weeks, preferably at intervals of 4 to 21 days.
  • Antibody-producing cells are collected 2-3 days after the last immunization.
  • Examples of antibody-producing cells include spleen cells, lymph node cells, and peripheral blood cells.
  • spleen cells are used.
  • 100 g of antigen is used per mouse at a time.
  • the antibody titer in the blood of the immunized animal or the culture supernatant of the antibody-producing cell was selected.
  • the antibody titer is measured.
  • the antibody detection method include known techniques such as EIA (Enzym Immunoassay), RIA (Radio Immunase), ELISA (Enzyme Linked Immunosorbent Assay), and the like.
  • myeloma (myeloma) cells to be fused with antibody-producing cells cell lines derived from various animals such as mice, rats, humans and generally available to those skilled in the art are used.
  • a cell line having drug resistance and having the property that it cannot survive in a selective medium (for example, HAT medium) in an unfused state but can survive only in a fused state is used.
  • An 8-azaguanine resistant strain is generally used, and this cell line lacks hypoxanthine guanine phosphoribosyltransferase and cannot grow in hypoxanthine / aminopterin / thymidine (HAT) medium! / It is.
  • HAT hypoxanthine guanine phosphoribosyltransferase and cannot grow in hypoxanthine / aminopterin / thymidine (HAT) medium! / It is.
  • Myeloma cells are known in various cell lines such as P3 (P3x63Ag8.653) (J. Immunol. (1979) 123: 1548-1550), P3x63Ag8U.1 (Current Topics in Microbiology and Immunology (1978). 81: 1—7), NS—l (Kohler, G. and Milstein, C., Eur. J. Immunol. (1976) 6: 511—519), MPC—11 (M argulies, DH et al., Cell (1976) 8: 405-415), SP2 / 0 (Shulman, M. et al., Nature (1978) 276: 269-270), FO (de St.
  • Antibody-producing cells can be obtained from spleen cells, lymph node cells, and the like. That is, the spleen, lymph nodes, etc. are removed or collected from the various animals, and these tissues are crushed. The resulting disrupted product is suspended in a medium or buffer such as PBS, DMEM, RPMI1640, etc., filtered through a stainless steel mesh, etc., and centrifuged to prepare the desired antibody-producing cells.
  • a medium or buffer such as PBS, DMEM, RPMI1640, etc.
  • the myeloma cells and antibody-producing cells are fused.
  • Cell fusion is carried out by mixing myeloma cells and antibody-producing cells at a mixing ratio of 1: 1 to 1:10 in an animal cell culture medium such as MEM, DMEM, RPME-1640 medium, It is performed by contacting at 30-37 ° C for 1-15 minutes.
  • a fusion promoter such as polyethylene glycol, polyvinyl alcohol or Sendai virus having an average molecular weight of 1,000 to 6,000 or a fusion virus can be used.
  • antibody-producing cells and myeloma cells can be fused using a commercially available cell fusion device using electric stimulation (for example, electoral position).
  • the target hyperidoma is selected from the cells after cell fusion treatment.
  • Examples of the method include a method utilizing selective growth of cells in a selective medium. In other words, after diluting the cell suspension with an appropriate medium, it is spread on a microtiter plate, and a selective medium (such as HAT medium) is added to each well. As a result, growing cells can be obtained as hybridomas.
  • the screening of wild and ibridoma is performed by limiting dilution method, fluorescence excitation cell sorter method, etc., and finally monoclonal antibody-producing hyperidoma is obtained.
  • Examples of a method for collecting monoclonal antibodies with the acquired nodobridoma power include ordinary cell culture methods and ascites formation methods.
  • Hypridoma is cultured in an animal cell culture medium such as RPMI-1640 medium containing 10-20% urine fetal serum, MEM medium, or serum-free medium under normal culture conditions (for example, 37 ° C, Incubate for 2-14 days at 5% CO concentration)
  • Antibodies are obtained from the culture supernatant.
  • hypridoma is administered in the abdominal cavity of animals of the same kind as mammals derived from myeloma cells, and the amount of hyperidoma is increased in large quantities. Let it grow. Ascites or serum is collected after 1 to 4 weeks.
  • the antibody collection method requires purification of the antibody, a known method such as an ammonium sulfate salting-out method, ion exchange chromatography, or affinity chromatography is appropriately selected. Or by combining them.
  • a known method such as an ammonium sulfate salting-out method, ion exchange chromatography, or affinity chromatography is appropriately selected. Or by combining them.
  • an antigen binds to an antibody, or binds to a specific receptor such as B lymphocyte or T lymphocyte to cause antibody production and an immune reaction such as Z or cytotoxicity (eg, protein, Lipids, sugars, etc., but are not limited to these).
  • an antibody or lymphocyte receptor is called “antigenicity”.
  • Properties that induce immune responses such as antibody production are called “immunogenicity”.
  • Substances used as antigens include, for example, at least one target substance (eg, protein).
  • the contained substance is preferably full length, but may be a partial sequence as long as it contains at least one epitope capable of inducing immunity.
  • epitope or “antigenic determinant” refers to a site in an antigen molecule to which an antibody or lymphocyte receptor binds. Methods for determining epitopes are well known in the art, and such epitopes can be determined by those skilled in the art using such conventional techniques once the primary sequence of the nucleic acid or amino acid is provided. .
  • Epitopes can be used without necessarily knowing their exact location and structure. Thus, epitopes require a set of amino acid residues involved in recognition by specific immunoglobulins, or in the case of T cells, recognition by T cell receptor proteins and Z or major histocompatibility complex (MHC) receptors. A set of amino acid residues is included. The term is also used interchangeably with “antigenic determinant” or “antigenic determinant site”. In the immune system field, in vivo or in vitro, epitopes are molecular features (e.g., primary peptide structure, secondary peptide structure or tertiary peptide structure and charge) and are recognized by immunoglobulins, T cell receptors or HLA molecules. Forming a site.
  • MHC major histocompatibility complex
  • Epitopes containing peptides may contain more than two amino acids in a spatial conformation unique to the epitopes.
  • epitopes consist of at least 5 such amino acids, typically consisting of at least 6, 7, 8, 9, or 10 such amino acids.
  • the length of the epitope is longer However, it is generally preferred because it resembles the antigenicity of the original peptide, but this is not always the case when considering conformation.
  • Methods for determining the spatial conformation of amino acids are known in the art and include, for example, X-ray crystallography and two-dimensional nuclear magnetic resonance spectroscopy.
  • identification of epitopes in a given protein is readily accomplished using techniques well known in the art. For example, Geysen et al. (1984) Proc.
  • a sequence of at least 3 amino acids in length is required for use as a peptide containing peptide, preferably this sequence is at least 4 amino acids, more preferably at least 5 amino acids, at least 6 amino acids.
  • a sequence of at least 7 amino acids, at least 8 amino acids, at least 9 amino acids, at least 10 amino acids, at least 15 amino acids, at least 20 amino acids, at least 25 amino acids may be required.
  • Epitopes can be linear or conformational.
  • Certain amino acids can be converted to other amino acids without any apparent loss or loss of interaction binding capacity, for example, in the protein structure such as a carbohydrate binding region, cysteinylation region, cationic region, or substrate molecule binding site. Can be replaced. It is the ability and nature of the protein to define the biological function of a protein. Thus, specific amino acid substitutions can be made in the amino acid sequence or at the level of its DNA coding sequence, resulting in a protein that still retains its original properties after substitution. Accordingly, various modifications are disclosed herein without apparent loss of biological utility. Or the corresponding DNA encoding this peptide.
  • hydrophobicity index of amino acids can be considered.
  • the importance of the hydrophobic amino acid index in conferring interactive biological functions in proteins is generally recognized in the art (Kyte. J and Doolittle, RFJ Mol. Biol. 157 (1): 105-132, 1982).
  • the hydrophobic nature of amino acids contributes to the secondary structure of the protein produced, and then defines the interaction of the protein with other molecules (eg, enzymes, substrates, receptors, DNA, antibodies, antigens, etc.).
  • Each amino acid is assigned a hydrophobicity index based on their hydrophobicity and charge properties.
  • the hydrophobicity index is preferably within ⁇ 2, more preferably within ⁇ 1, and even more preferably within ⁇ 0.5. It is understood in the art that such substitution of amino acids based on hydrophobicity is efficient.
  • hydrophilicity index is also useful for modifying the amino acid sequence of the present invention.
  • the following hydrophilicity indices have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartic acid (+ 3.0 ⁇ 1); glutamate (+ 3.0 ⁇ 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0) Threonine (one 0.4); proline (one 0.5 ⁇ 1); alanine (one 0.5); histidine (-0.5); cystine (one 1.0); methionine (one 1.3) Valine (one 1.5); leucine (one 1.8); isoleucine (one 1.8); tyrosine (one 2.3); ferulalanine (one 2.5); Tohuan (1 3.4).
  • an amino acid can be replaced with another that has a similar hydrophilicity index and still can provide a biological equivalent.
  • the hydrophilicity index is preferably within ⁇ 2, more preferably within ⁇ 1, and even more preferably within ⁇ 0.5.
  • conservative substitution means that the amino acid substitution is similar to the hydrophilicity index or Z and hydrophobicity index with the amino acid substituted with the original amino acid as described above. This refers to substitution. Examples of conservative substitutions are well known to those skilled in the art and include, for example, substitutions within the following groups: arginine and lysine; glutamic acid and aspartic acid; serine and threonine; glutamine and asparagine; and palin, leucine, and isoleucine However, it is not limited to these.
  • variant refers to a substance in which a part of the original substance such as a polypeptide or polynucleotide has been changed. Such variants include substitutional variants, addition variants, deletion variants, truncated variants, allelic variants, and the like. Alleles are genetic variants that belong to the same locus and are distinguished from each other. Therefore, an “allelic variant” refers to a variant that has an allelic relationship with a gene.
  • a “species homologue or homolog” is a homology (preferably at least 60% homology, more preferably at least 80%, at a certain amino acid level or nucleotide level within a species.
  • ortholog also called orthologous gene, refers to a gene derived from speciation from a common ancestor with two genes. For example, taking the hemoglobin gene family with multiple gene structures as an example, human and mouse ⁇ -hemoglobin genes are orthologs. Human ⁇ -hemoglobin genes and / 3 hemoglobin genes are paralogs (genes generated by gene duplication). It is.
  • nucleic acid sequences As used herein, “conservative (modified) variants” applies to both amino acid and nucleic acid sequences.
  • Conservatively modified with respect to a particular nucleic acid sequence refers to a nucleic acid that encodes the same or essentially the same amino acid sequence, where the nucleic acid is an amino acid. When no acid sequence is encoded, it refers to an essentially identical sequence. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For example, the codons GCA, GCC, GCG, and GCU all encode the amino acid alanine.
  • nucleic acid variations are “silent modifications (mutations),” which are one species of conservatively modified mutations.
  • Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of that nucleic acid.
  • each codon in nuclear acid except AUG, which is usually the only codon for methionine, and TGG, which is usually the only codon for tryptophan
  • 1S produces functionally identical molecules It is thus understood that this can be modified.
  • each silent variation of a nucleic acid that encodes a polypeptide is implicit in each described sequence.
  • modifications can be made to avoid substitution of cystine, an amino acid that significantly affects the conformation of the polypeptide.
  • amino acid additions, deletions, or modifications can also be made in order to produce functionally equivalent polypeptides.
  • Amino acid substitution refers to substitution of the original peptide with one or more, for example, 1 to: LO, preferably 1 to 5, more preferably 1 to 3 amino acids.
  • the addition of amino acids means that one or more, for example, 1 to 10, preferably 1 to 5, more preferably 1 to 3 amino acids are added to the original peptide chain.
  • Deletion of amino acids refers to deletion of one or more, for example, 1 to 10, preferably 1 to 5, more preferably 1 to 3 amino acids from the original peptide.
  • Amino acid modifications include, but are not limited to, amidation, carboxylation, sulfation, halogenation, alkylation, glycosylation, phosphorylation, hydroxylation, acylation (eg, acetylation), and the like.
  • the substituted or added amino acid may be a natural amino acid or a non-natural amino acid, or an amino acid analog. Natural amino acids are preferred.
  • substitution, addition or deletion of a polypeptide or polynucleotide refers to an amino acid or its substitute, or nucleotide, respectively, with respect to the original polypeptide or polynucleotide. Or replace or add to its substitute power Or to be removed.
  • substitution, addition, or deletion techniques are well known in the art, and examples of such techniques include site-directed mutagenesis techniques. Any number of substitutions, additions or deletions is acceptable as long as it is one or more. Such a number retains the desired function (for example, marker, etc.) in the variant having the substitution, addition or deletion. You can do as much as you can. For example, such a number can be 1 or several, and is preferably within 20%, within 10%, or less than 100, less than 50, less than 25, etc. of the total length. possible.
  • diagnosis refers to identifying various parameters related to a disease, disorder, or condition in a subject and determining the current state or future of such a disease, disorder, or condition.
  • the state of the body can be investigated, and such information can be used to treat a disease, disorder, condition, treatment to be administered or prevention in a subject.
  • Various parameters such as formulation or method can be selected.
  • diagnosis in a narrow sense refers to diagnosis of the current state, but includes “pre-diagnosis” in a broad sense.
  • preliminary diagnosis refers to detecting the stage before the onset of diabetes when referring to diabetes, for the purpose of determining the risk of future onset and preventing diabetes. Including determining whether there is a risk of suffering from diabetes.
  • the state of the body can be examined in advance, and such information can be used to treat a disease, disorder, condition, treatment to be administered or prevention in a subject.
  • Various parameters such as formulation or method can be selected.
  • the diagnostic method of the present invention is industrially useful because, as a general rule, it is possible to use the physical strength, and it can be performed away from the hands of medical personnel such as doctors. .
  • it may be specifically referred to as “preliminary diagnosis or support for diagnosis”.
  • treatment refers to such a condition for a disease or disorder. In such a case, it means preventing, preferably maintaining the status quo, more preferably reducing, and even more preferably eliminating such a disease or disorder.
  • the concentration of at least one of these three proteins in blood is measured as a marker substance for diabetes. Diabetes is diagnosed by comparing the measured value with a healthy value.
  • diagnosis of diabetes refers to determining whether or not there is a risk of developing diabetes for the purpose of preventing diabetes, not just determining whether or not the patient has diabetes. Includes monitoring of condition and recurrence.
  • the concentration of only a part of the three types of marker substances may be measured! / Or the concentration of all three types may be measured.
  • a multi-marker system can be used to diagnose diabetes with multidirectional power, and the diagnosis is highly accurate.
  • these three kinds of proteins are also present in the blood of healthy subjects, by monitoring the fluctuations in the concentration, it is possible to detect signs that the healthy subjects will develop diabetes.
  • the method for diagnosing a disease of the present invention comprises comparing at least one concentration of the marker substance (eg, (a) to (n)) in a body fluid of a subject with a healthy value, and It is used to determine the presence or future risk of onset.
  • the marker substance eg, (a) to (n)
  • the disease diagnosis method of the present invention since another marker substance is used as an index instead of using blood glucose as a direct index, it is possible to capture the state before the blood glucose level rises. As a result, in addition to the presence or absence of diabetes, the risk of developing future diabetes can be determined.
  • pre-diagnosis of diabetes and “determining future risk of developing diabetes” are used interchangeably, and there is a possibility (risk) of having diabetes in the future when diabetes does not occur. Determining whether or not there is a possibility or the degree of possibility (risk).
  • the values of “about 7040”, “about 8330”, “about 8530”, etc. of the mass Z charge ratio (hereinafter sometimes abbreviated as “MZZ”) in each marker substance are the mass. This is a value that takes into account the error range of the measured values in the analysis, and generally has a range of ⁇ 0.2%. That is, approximately 7040 represents approximately 7040 ⁇ 0.2%, approximately 8330 approximately 8330 ⁇ 0.2%, and approximately 8530 approximately 8530 ⁇ 0.2%.
  • the other mass Z charge ratios have a width of approximately ⁇ 0.2% in a similar manner.
  • all of these marker substances are proteins mainly present in blood.
  • the marker substances in body fluids (a), (b), (c), (d), (e), ( The concentrations of f), (g), (h) and (i) are higher, and the concentrations of marker substances (k), (1), (m) and (n) are lower.
  • a carrier on which a substance having affinity for a marker substance is immobilized is used. Then, a bodily fluid or bodily fluid component is brought into contact with the carrier, and the marker substance contained in the bodily fluid or bodily fluid component is captured on the carrier via a substance having affinity for the marker substance, and the amount of the trapped marker substance Based on the above, the concentration of the marker substance in the body fluid is calculated. According to the disease diagnosis method of the present invention, since the marker substance captured on the carrier is the measurement target, the influence of the contaminant substance contained in the measurement sample can be reduced, and the sensitivity and precision can be increased. The concentration of marker substances can be measured. Examples of the body fluid component include serum or plasma when the body fluid is blood.
  • a carrier having a planar portion is used, and the substance having affinity for the marker substance is immobilized on a part of the planar portion.
  • the substance having affinity for the marker substance can be fixed in spots on a plurality of locations on the carrier.
  • the concentration of the marker substance can be measured even with a very small amount of measurement sample.
  • An example of the carrier having a flat surface portion is a substrate such as a chip.
  • an ion exchanger, metal chelate or antibody is used as the substance having affinity for the marker substance, and the ion exchanger, metal chelate or The marker substance in the measurement sample is captured on the carrier via the antibody.
  • the material force ion exchanger or metal chelate various types are easily available, and a carrier for capturing the marker substance can be easily prepared.
  • the substance is an antibody, the marker substance can be captured more specifically. Methods for measuring the amount of marker substance captured include mass spectrometry and immunoassay. (In the case of antibodies).
  • system refers to any system for diagnosis, generally one or more component forces, where there are multiple components that interact with each other. In other words, it is a system that satisfies the three conditions of harmonizing behavior and function as a whole.
  • the system can be in any form, such as a device, composition, diagnostic agent. Therefore, the system includes, for example, a large-scale system including a measuring device, a system including a chromatographic system, a kit using an immune reaction, a composition including an antibody (that is, a marker substance including a monoclonal antibody). And diagnostic agents that are in-vitro drugs).
  • screening refers to selecting a target such as an organism or substance having a specific target property from a large number of populations using a specific operation Z evaluation method.
  • an agent eg, antibody
  • polypeptide or nucleic acid molecule of the invention can be used.
  • the screening may be performed using a library generated using an in silico (computer system) system that may use a system using a real substance such as in vitro or in vivo.
  • in silico computer system
  • compounds obtained by screening having the desired activity are also included within the scope of the present invention.
  • the present invention contemplates providing a drug by computer modeling based on the disclosure of the present invention.
  • the present invention relates to a candidate combination that modulates the ability to bind to, or the activity of, a protein of the present invention or a polypeptide of the present invention, or a biologically active portion thereof.
  • Test compounds of the present invention can be obtained using any of a number of approaches in a combinatorial library method known in the art, including: biological libraries; spatial Accessible parallel solid phase or solution phase live Rally; one synthetic library method that requires deconvolution; one “one bead one-rich” library method; and one synthetic library method using affinity chromatography selection.
  • the biological library approach is limited to peptide libraries, but the other four approaches are applicable to small libraries of peptides, non-peptide oligomers or compounds (Lam (1997) Anticancer Drug Des. 12 : 145).
  • the present invention provides a straightforward structural activity by a computer as a tool for screening an agent that is as effective as the active ingredient of the present invention (eg, polypeptide or nucleic acid).
  • an agent that is as effective as the active ingredient of the present invention (eg, polypeptide or nucleic acid).
  • QSAR quantitative structure activity relationship
  • the computer technology includes creation of a substrate cage type, a pharmacophore, and a homology model of the active site of the present invention produced by several computers.
  • methods for modeling the normal characteristic groups of an interacting substance for a substance from in vitro data are described in the CATALYST TM pharmacophore method (Ekins et al.
  • Fitting of a compound to the active site can be performed using any of a variety of computer modeling techniques known in the art. Visual inspection and manual manipulation of compounds to active sites are described in QUANTA (Molecular Simulations, Burlington, MA, 1992), SYBYL (Molecular Modeling Software, Tripos Associates, Inc., St. Louis, MO, 1992), AMBER (Weiner et a 1., J. Am. Chem. Soc., 106: 765-784, 1984), CHARMM (Brooks et a 1., J. Comp. Chem., 4: 187-217, 1983), etc. You can use a program like this. In addition, energy can be minimized by using a standard force field such as CHARMM, AMBER, etc.
  • composition containing the substance obtained by the screening method of the present invention can be provided in any preparation form as long as it is in a form suitable for transfer to an organism.
  • formulation forms include solutions, injections, and sustained release agents.
  • administration routes include oral administration, parenteral administration, and direct administration to the affected area.
  • kit refers to a unit provided with a part to be provided (eg, antibody, label, etc.) usually divided into two or more compartments. This kit form is preferred when it is intended to provide a composition that should preferably be mixed and used immediately prior to use.
  • a kit preferably comprises a provided part (eg, instructions or instructions describing how the reagent should be processed).
  • the kit When used as a reagent kit, the kit usually includes instructions describing how to use the antibody.
  • the "instruction” describes an explanation for a person who administers a method of administering the medicine of the present invention, such as a doctor or a patient.
  • This instruction manual describes a word for instructing how to use the diagnostic agent of the present invention or administering a medicine or the like.
  • the instructions may include a word indicating that administration is performed to skeletal muscle (for example, by injection) as an administration site.
  • This instruction is prepared in accordance with the format prescribed by the national supervisory authority (for example, the Ministry of Health, Labor and Welfare in Japan, the Food and Drug Administration (FDA) in the United States, etc.) in the country where the present invention is implemented, and approved by the regulatory authority. It is clearly stated that it has been received. Instructions are so-called package inserts, usually provided in paper form, but not limited to it, for example, in the form of electronic media (e.g. home page provided by the Internet, e-mail). But it can be provided.
  • subject refers to an organism to which the treatment of the present invention is applied, and is also referred to as "patient”.
  • patient refers to an organism to which the treatment of the present invention is applied, and is also referred to as “patient”.
  • patient or subject may preferably be a human.
  • in vivo refers to the inside of a living body.
  • in vivo refers to the location where a target substance is to be placed.
  • in vitro refers to a state in which a part of a living body is removed or released “outside the living body” (for example, in a test tube) for various research purposes. It is a term that contrasts with in vivo.
  • ex vivo refers to a case where target cells for gene transfer are extracted from a subject, a therapeutic gene or factor is introduced in vitro, and then returned to the same subject again. A series of operations is called ex vivo.
  • polypeptides, nucleic acids, pharmaceuticals used in the present invention, and compositions prepared by such polypeptides or nucleic acids may be in any formulation form as long as they are in a form suitable for transfer to an organism.
  • examples of such a preparation form include liquids, injections and sustained-release agents.
  • Administration methods include oral administration and parenteral administration (e.g., intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, mucosal administration, rectal administration, intravaginal administration, topical administration to affected areas, skin administration, etc.) And direct administration to the affected area.
  • Formulations for such administration can be provided in any pharmaceutical form. Examples of such a preparation form include liquids, injections, and sustained release agents.
  • compositions and medicaments of the present invention may be in the form of orally acceptable aqueous solutions that do not contain pyrogens when administered systemically.
  • the preparation of such pharmaceutically acceptable protein solutions is within the skill of the artisan, provided that considerable attention is paid to pH, isotonicity, stability, and the like.
  • the solvent used for pharmaceutical formulation in the present invention may have either aqueous or non-aqueous properties.
  • the vehicle can be used to modify or maintain the pH, osmolality, viscosity, clarity, color, sterility, stability, isotonicity, disintegration rate, or odor of the formulation. It may contain material.
  • the compositions of the present invention may include other formulation materials to modify or maintain the release rate of the active ingredient or to facilitate absorption or permeation of the active ingredient.
  • the prescription procedure of the preparation of the present invention is known in the art, and is described in, for example, the Japanese Pharmacopeia, the US Pharmacopeia, the pharmacopoeia of other countries, and the like. Thus, one skilled in the art can determine the amount to be administered without undue experimentation as described herein.
  • the present invention includes a marker substance in a sample derived from a subject, a factor that specifically interacts with the single substance, or a means for selectively recognizing the marker substance.
  • a marker substance in a sample derived from a subject, a factor that specifically interacts with the single substance, or a means for selectively recognizing the marker substance.
  • the present invention provides a system or composition for pre-diagnosing whether a subject is diabetic, comprising a marker substance in a sample from the subject.
  • the present invention provides a system for pre-diagnosing whether a subject is diabetic or comprising a factor that specifically interacts with a marker substance in a sample derived from the subject.
  • a composition is provided.
  • the present invention provides a system for pre-diagnosing whether a subject is diabetic, comprising means for selectively recognizing a marker substance in a sample derived from a subject. provide.
  • the present invention provides a system or composition for diagnosing whether a subject is diabetic, comprising a marker substance in a sample derived from the subject.
  • the present invention provides a system for diagnosing whether a subject is diabetic or comprising a factor that specifically interacts with a marker substance in a sample derived from a subject.
  • a composition is provided.
  • the present invention provides a system for diagnosing whether a subject is diabetic, comprising means for selectively recognizing a marker substance in a sample derived from a subject. To do.
  • the marker substance or system can identify the marker substance, the marker substance in a sample from any subject, a factor that specifically interacts with the marker substance, or the It can be appreciated that means for selectively recognizing the marker substance can be used. Therefore, the factors or procedures specifically described herein It is understood that any equivalent factor or means known in the art can be used, not just the stage.
  • the marker substance used is characterized in that it is present in the body fluid, preferably blood of the subject. This is because if the body fluid is desired to be bound by theory, the post-treatment after removal is simple, and a large amount of diagnosis or diagnosis support is possible. While not wishing to be bound by theory, blood is preferred because it significantly reflects the behavior of the marker substance of the present invention.
  • the marker substance used in the present invention is characterized in that it is a gene product.
  • the gene product is one that has not been previously known to be directly related to sugar metabolism. This is because it has not been known so far that even markers that are known to be directly related to glucose metabolism can be diagnosed or pre-diagnosed as marker substances for diabetes. This is because diagnosis can be performed.
  • the marker substance identified in the present invention has been shown to be a marker in model animals, and can vary depending on a number of etiologies, such as markers that have been found empirically in humans. In many cases, it is unclear whether diabetes is caused only by the disease, but the marker substance of the present invention does not have such an ambiguity. This is because the marker substance of the present invention has been found as a result of comprehensive analysis using a protein chip, and has the power to confirm in a model animal.
  • the marker substance used in the present invention is transthyretin, transthyretin derivative, apolipoprotein CII, apolipoprotein CII derivative, apolipoprotein cm, apolipoprotein cm derivative and serum albumin and These include one or more substances that are selected from the group of corresponding protein forces.
  • 2 or more, 3 or more or more marker substances in particular, a plurality of marker substances selected from different groups when each paired with a derivative is regarded as one group
  • the factor used in the present invention is a nucleic acid molecule, a polypeptide. , Lipids, sugar chains, small organic molecules and complex molecules thereof.
  • the factor is a protein or complex molecule (eg, glycoprotein, lipid protein, etc.).
  • the factor is an antibody (eg, a polyclonal antibody or a monoclonal antibody).
  • Such factors are preferably labeled or labelable. This is because it is easy to diagnose.
  • label refers to an entity (such as a substance, energy, electromagnetic wave, etc.) for identifying other molecules or substances of interest.
  • labeling methods include RI (radioisotope) method, fluorescence method, piotin method, chemiluminescence method and the like.
  • RI radioisotope
  • fluorescence method fluorescence method
  • piotin method piotin method
  • chemiluminescence method chemiluminescence method and the like.
  • the labeling is performed with fluorescent substances having different fluorescence emission maximum wavelengths. The difference in the maximum fluorescence emission wavelength is preferably lOnm or more. Any fluorescent substance can be used as long as it can bind to the base moiety of nucleic acid.
  • Cyanine dyes eg, CyDye TM series Cy3, Cy5, etc.
  • rhodamine 6G reagent N-acetoxy N2-acetylene
  • minofluorene AAF
  • AAIF iodine derivative of AAF
  • fluorescent substances having a difference in fluorescence emission maximum wavelength of lOnm or more include a combination of Cy5 and rhodamine 6G reagent, a combination of Cy3 and fluorescein, a combination of rhodamine 6G reagent and fluorescein, etc.
  • such a label can be used to modify the target object so that it can be detected by the detection means used. Such modifications are known in the art, and those skilled in the art can appropriately carry out such methods depending on the label and the target object.
  • the means used are mass spectrometer, nuclear magnetic resonance analyzer, X-ray analyzer, SPR, chromatography (eg, HPLC, thin layer chromatography, gas chromatography). ), Immunological means (eg, Western plotting, ELISA, RIA), biochemical means (eg, pi electrophoresis, Southern blotting, two-dimensional electrophoresis), electrophoresis equipment, chemical analysis equipment, fluorescent fluorescence Dimensional differential electrophoresis (2DE—DIGE), isotope labeling (ICAT), tandem purification (TAP), physical means, laser microdissection and combinations thereof Is selected from the group.
  • Immunological means eg, Western plotting, ELISA, RIA
  • biochemical means eg, pi electrophoresis, Southern blotting, two-dimensional electrophoresis
  • electrophoresis equipment chemical analysis equipment
  • ICAT isotope labeling
  • TAP tandem
  • the system of the present invention further comprises a standard of marker substance.
  • a standard of marker substance confirms whether the marker substance detection means (such as a factor that specifically interacts with the marker substance or a means for selectively recognizing the marker substance) is functioning normally. Preferred to use for.
  • the present invention may further comprise means for purifying the sample of interest.
  • purification means include chromatography. Because refinement can increase the accuracy of the diagnosis, it can be used in a preferred embodiment. This is not essential.
  • the subject includes a mammal, and in one embodiment, the subject includes a rodent.
  • rodents for example, rats, mice, etc.
  • model animals particularly diabetic model animals, have been prepared.
  • the subject includes a human.
  • the factor or means used in the present invention has the ability to quantify a single substance of the present invention.
  • Such quantification is preferably a means or factor that allows a standard curve to be drawn properly when a standard curve is drawn.
  • Preferable examples include antibodies, mass spectrometry, and chromatographic analysis. Therefore, in one embodiment, the system of the present invention further includes a quantification means for quantifying the marker substance.
  • the quantification unit includes a determination unit that compares a standard curve with a measurement result to determine whether the marker substance is within a normal value range.
  • a determination means can be realized using a computer.
  • the system of the present invention is a composition comprising a marker substance or the agent that specifically interacts with the marker substance.
  • the marker substance of interest in the system of the present invention includes at least one substance selected from the group consisting of transthyretin and transthyretin derivative power
  • the transthyretin derivative contains S-cystine- Letransthyretin, Dal Tathionized transthyretin, S—S bond-forming transthyretin, oxidation (eg, oxidation of methionine side chain) transthyretin, formylated transthyretin, acetylated transthyretin, phosphorylated transthyretin, sugar Examples include chain transthyretin and myristino transthyretin.
  • S-cystinyl transthyretin is preferable.
  • the present invention examines the amount ratio between transthyretin and a transthyretin derivative (particularly, a metabolite appearing in the acid-reduction pathway), thereby reducing the severity or risk of diabetes. It should be obvious that the points you have found can be determined!
  • At least one phenomenon selected from the group consisting of a decrease in transthyretin and an increase in transthyretin inducer caloric is the ability to develop diabetes or the risk of future development. Is an indicator of high.
  • At least one phenomenon selected from the group consisting of a decrease in transthyretin and an increase in the amount of transthyretin derivatives is an indicator of the degree of developing diabetes or the risk of developing future It can be. It is understood that such indicators can be determined by those skilled in the art based on the description herein.
  • the transthyretin which is a subject of the present invention is the force encoded by the nucleic acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 3, or SEQ ID NO:
  • the transthyretin derivative of interest in the present invention is an amino acid sequence encoded by the nucleic acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 3, or SEQ ID NO: 2 or SEQ ID NO: 4.
  • the cysteine at position 30 (position 10 in the mature form) or a corresponding cysteine is cysteine-modified, or may have a modified sequence thereof.
  • the factor or means used in the present invention has the ability to distinguish between transthyretin monomers and tetramers.
  • the factor or means used in the present invention has the ability to differentiate between transthyretin and S-cysteine transthyretin (eg, antibody o Factors or means with such capabilities are, for example, antibodies, generating an antibody library and, from that library, transthyretin or S-cysteine transthyretin.
  • transthyretin and S-cysteine transthyretin eg, antibodies generating an antibody library and, from that library, transthyretin or S-cysteine transthyretin.
  • Such techniques can be achieved using techniques well known in the art. it can. In addition to antibodies, this can also be achieved using techniques well known in the art.
  • the factor or means in the present invention recognizes transthyretin and S-cysteinyl transthyretin, and the system of the present invention uses transthyretin and S-cysteinyl transthyretin.
  • a means for identifying is further provided. For example, by providing a combination of identification means such as antibody + electrophoresis and molecular weight, etc., transthyretins are identified, but electrophoresis or mass spectrometry is used to distinguish derivatives from others. It is understood that identification can be achieved by using. Such techniques can be achieved using techniques well known in the art.
  • the factor or means in the present invention recognizes transthyretin and S-cysteinyl transthyretin, and the system of the present invention uses the molecular weight of transthyretin and the molecular weight of S-cysteinyl transthyretin. And a means for measuring the relative ratio of transthyretin to S-cysteine transthyretin. By providing such a system, the present invention can determine the degree of deterioration of diabetes and the onset probability.
  • the marker substance used in the system of the present invention includes apolipoprotein CII or apolipoprotein CII derivative, and examples of the apolipoprotein CII derivative include proapolipoprotein CII.
  • At least one phenomenon selected from the group consisting of apolipoprotein CII reduction and apolipoprotein CII derivative variability has a risk of developing diabetes or a high risk of developing in the future, Can be an indicator of this.
  • apolipoprotein CII reduction and apolipoprotein CII induction The degree of onset of diabetes is at least one phenomenon selected from the group
  • the risk of future onset may be an indicator of height.
  • the target apolipoprotein CII is a force encoded by the nucleic acid sequence shown in SEQ ID NO: 5 or SEQ ID NO: 7, or SEQ ID NO: 6 or SEQ ID NO: It has the amino acid sequence shown in 8 or a modified sequence thereof.
  • the target blower polypoprotein CII may be one in which the lead sequence is bound to the above sequence.
  • the factor or means used in the present invention has the ability to selectively identify apolipoprotein CII (eg, an antibody).
  • a factor or means having such a capability is to prepare a library of antibodies, and to specifically select apolipoprotein CII from the library (preferably, selective). Ii) can be made by selecting those that react, and such techniques can be achieved using techniques well known in the field. Similarly, other than antibodies can also be achieved in this field using well-known techniques.
  • the factor or means in the present invention has the ability to selectively identify apolipoprotein CI I, and the system comprises means for quantifying the apolipoprotein CII.
  • the present invention can determine the degree of deterioration of diabetes and the onset probability.
  • the marker substance used in the system of the present invention includes apolipoprotein cm or apolipoprotein cm derivative, and the apolipoprotein cin is apolipoprotein cni, and the apolipoprotein
  • the 0 cni derivative is selected from the group consisting of apolipoprotein cm and apolipoprotein force.
  • Akira is apolipoprotein cni apolipoprotein polypoprotein
  • One phenomenon is an indicator of the ability to develop diabetes or an increased risk of developing it in the future.
  • One phenomenon can be an indicator of the degree of onset of diabetes or the risk of future onset. It will be understood that such indicators can be determined by those skilled in the art based on the description herein.
  • the target apolipoprotein cm is a force encoded by the nucleic acid sequence represented by SEQ ID NO: 9 or SEQ ID NO: 11, or SEQ ID NO: 10 or sequence. It has the amino acid sequence shown in No. 12 (pro form), a form lacking 20 amino acids at the N-terminal thereof (mature form), or a modified sequence thereof. Preferably, it has a sequence lacking the first 20 C-terminal amino acids.
  • the apolipoprotein cm derivative of interest is a force encoded by the nucleic acid sequence represented by SEQ ID NO: 9 or SEQ ID NO: 11, or SEQ ID NO: 10 or 12, respectively.
  • a force that is a derivative having a sugar chain at 94-position or 95-position or the corresponding threonine, or these forces also have a form lacking the 20 amino acids at the N-terminus.
  • it has a sequence lacking the first 20 C-terminal amino acids.
  • the factor or means used in the present invention has the ability to distinguish between apolipoprotein cm and apolipoprotein CIII derivatives.
  • the factor or means used in the present invention is at least two of apolipoprotein CIII, apolipoprotein CIII and apolipoprotein CIII.
  • the factor or means having such ability is, for example, an antibody library if it is an antibody, and further, apolipoprotein CIII, apolipoprotein cni and apolipoprotein are selected from the library.
  • the factor or means of the present invention has the ability to distinguish all of apolipoprotein CI II, apolipoprotein CIII and apolipoprotein CIII.
  • a factor or means having such a capability is to prepare an antibody library, and further, from the library, apolipoprotein CIII, apolipoprotein CIII, and apolipoprotein CIII.
  • the factor or said means comprises an antibody having the ability to distinguish between apolipoprotein cm and apolipoprotein cm derivatives, preferably apolipoprotein CIII, apolipoprotein CIII and Less of apolipoprotein CIII
  • 0 1 2 Including an antibody capable of distinguishing at least two, apolipoprotein CIII and apolipo
  • the factor or means in the present invention is apolipoprotein CI
  • the system further comprises means for discriminating between apolipoproteins ci wrinkles and apolipoprotein cm derivatives. For example, by providing a combination of identification means such as antibody + electrophoresis and molecular weight etc., apolipoprotein cms can be identified, but electrophoresis or mass spectrometry etc. to distinguish between derivatives and others It is understood that identification can be achieved by using. Such a technique can be achieved using techniques well known in the art.
  • the factor or means of the present invention is apolipoprotein CI
  • the system of the present invention is capable of at least two of apolipoprotein CIII, apolipoprotein CIII and apolipoprotein CIII.
  • apolipoprotein cms use electrophoresis or mass spectrometry to discriminate between force derivatives to identify and others by providing a combination of identification means by molecular weight etc. such as antibody + electrophoresis It is understood that identification can be achieved. Such a technique can be achieved by using a well-known technique in this field.
  • the factor or means in the present invention is apolipoprotein CI
  • the present invention can determine the degree of diabetes and the onset probability.
  • the marker substance used in the system of the present invention includes serum albumin or a serum albumin derivative
  • the serum albumin derivative includes acidified serum albumin, fractionated serum albumin, and the like.
  • At least one phenomenon selected from the group that also has a decrease in serum albumin and a variability in serum albumin derivatives is developing diabetes or having a high risk of developing in the future. It is an indicator.
  • Albumin is a power that is measured as an index of various diseases. It has never been known that albumin is an index of diabetes. In particular, it is worth noting that it has been found for the first time to increase the accuracy of diagnosis when combined with transthyretin, apolipoprotein cn, apolipoprotein IV, and the like.
  • At least one phenomenon selected from the group consisting of serum albumin reduction and serum albumin derivative variability is an indicator of the degree of developing diabetes or the risk of high future development. It is understood that such an indicator can be determined by those skilled in the art based on the description of this specification.
  • the subject serum albumin is a force encoded by the nucleic acid sequence shown in SEQ ID NO: 13 or SEQ ID NO: 15, or SEQ ID NO: 14 or SEQ ID NO: It has the amino acid sequence shown in 16 or a modified sequence thereof. Alternatively, it may have a known serum albumin sequence in addition to the forces described herein.
  • the factor or means used in the present invention has the ability to selectively distinguish serum albumin (eg, an antibody).
  • serum albumin eg, an antibody
  • an antibody library is prepared, and a library that reacts specifically (preferably, selectively) with serum albumin is selected from the library.
  • a technique can be achieved using known techniques in the art.
  • antibodies other than antibodies this can be achieved using known techniques in the art.
  • the factor or means in the present invention has the ability to selectively distinguish serum albumin, and the system comprises means for quantifying the serum albumin.
  • the system comprises means for quantifying the serum albumin.
  • identification means based on molecular weight such as antibody + electrophoresis
  • serum albumins have the ability to identify Use electrophoresis or mass spectrometry to distinguish between serum albumin itself and others It is understood that identification can be achieved. Such a technique can be achieved using techniques well known in the art.
  • system of the present invention can be preferably used as a diagnostic agent
  • the invention provides a method for prediagnosis or diagnosis of whether a subject is diabetic or to support the prediagnosis or diagnosis comprising: A) in a sample from the subject Providing a method comprising: measuring a marker substance; and B) determining from the measurement results whether the subject is diabetic or likely.
  • any means may be used for obtaining the sample.
  • the process of determining whether or not there is diabetes may be carried out by judging whether it is abnormal compared to the normal value compared to each marker substance. it can.
  • the marker substance and the like to be used are listed in the sections (System), (Transthyretin), (Apolipoprotein CIII), (Apolipoprotein CII) and (Serum albumin) !, It is understood that any one or more of the features described in the above may be included as long as they do not conflict. [0224] (Use)
  • the present invention relates to a marker substance in a sample derived from a subject, a factor that specifically interacts with the single substance, or a means for selectively recognizing the marker substance. It provides use in the manufacture of a medicament for pre-diagnosis or diagnosis of diabetes.
  • the sample may be acquired by any means. Usually, when a person other than the doctor is engaged in the measurement, it may have been obtained by the doctor in some form. From the measurement results, the process of determining whether or not diabetes is possible can be carried out by determining whether it is abnormal compared to each marker substance compared to normal values. .
  • the marker substance and the like to be used are listed in the sections (System), (Transthyretin), (Apolipoprotein CIII), (Apolipoprotein CII) and (Serum albumin) !, It is understood that any one or more of the features described in the above may be included as long as they do not conflict.
  • the present invention provides a subject that is a marker substance in a sample derived from a subject, a factor that specifically interacts with the marker substance, or a means that selectively recognizes the marker substance.
  • a subject that is a marker substance in a sample derived from a subject, a factor that specifically interacts with the marker substance, or a means that selectively recognizes the marker substance.
  • any means may be used for obtaining the sample.
  • a person other than the doctor engages in the measurement it may have been acquired by the doctor in some form.
  • the step of determining whether or not there is a possibility of diabetes from the measurement result can be carried out by determining whether or not it is abnormal as compared with each marker substance compared with the normal value.
  • the marker substance and the like to be used are listed in the sections (System), (Transthyretin), (Apolipoprotein CIII), (Apolipoprotein CII) and (Serum albumin) !, It is understood that any one or more of the features described in the above may be included as long as they do not conflict.
  • the method for measuring the concentration of a marker substance can be used for protein quantification as long as the marker substance concentration can be specifically measured.
  • a generally used method can be used as it is. For example, various immunoassays, mass spectrometry (MS), chromatography, electrophoresis and the like can be used.
  • Imnoassay the concentration of a marker substance can be accurately measured even in a sample with a lot of contaminants.
  • immunoassays include classical methods such as sedimentation, agglutination, and hemolysis that directly or indirectly measure antigen-antibody conjugates, as well as an enzyme that has increased detection sensitivity in combination with a labeling method. Examples include Immunoassay (EIA), Radioimmunoassay (RIA), and Fluorescent Imnoassay (FIA).
  • EIA Immunoassay
  • RIA Radioimmunoassay
  • FIA Fluorescent Imnoassay
  • the antibody specific for the marker substance used in these immunoassays may be monoclonal or polyclonal.
  • Ion ion methods for measuring the concentration of marker substances by mass spectrometry include matrix-assisted laser desorption / lonizat ion (MALDI), electrospray ionization, Any force of ESI) is applicable.
  • MALDI matrix-assisted laser desorption / lonizat ion
  • Any force of ESI is applicable.
  • MALDI is preferred because it produces less multivalent ions.
  • MALDI-TOF-MS combined with a time-of-flight mass spectrometer (TOF) can measure the concentration of marker substances more accurately.
  • MSZMS using two mass spectrometers, the concentration of one marker substance can be measured more accurately.
  • the test material is subjected to SDS polyacrylamide gel electrophoresis (SDS-PAGE) to separate the target marker substance, and an appropriate dye or fluorescent substance is used. It is only necessary to stain the gel and measure the intensity and fluorescence intensity of the band corresponding to the target marker substance. If the marker substance cannot be separated by SDS-PAGE alone, two-dimensional electrophoresis combined with isoelectric focusing (IEF) can be used. Furthermore, the amount of marker substance on the membrane can be measured by performing Western plotting rather than detecting directly from the gel.
  • SDS-PAGE SDS polyacrylamide gel electrophoresis
  • the method for diagnosing diabetes of the present invention comprises (a) a protein having a molecular weight of about 13800, which is captured by a cation exchanger at a pH of 7.0 or lower, and (b) a metal at a pH of 7.0 or lower.
  • a protein with a molecular weight of about 8700 trapped by an ion-immobilization carrier (c) a protein with a molecular weight of about 9400 trapped by a cation exchanger at a pH of 7.0 or lower, or pH 7.0 (D) a protein having a molecular weight of about 9700, or (d) a protein having a molecular weight of about 9700, which is captured by a cation exchanger at a pH of 7.0 or less, or p A protein with a molecular weight of about 9700 that is captured on a metal ion-immobilized support at H7.0.
  • (E) A protein with a molecular weight of about 66000 that is captured by a cation exchanger at a pH of 7.0 or lower. Or a protein having a molecular weight of about 66000, trapped on a metal ion-immobilized carrier at pH 7.0, And a marker substance, the method also including comparing the amount of blood and healthy value.
  • the physical properties of the above (a), (b), (c), (d), and (e) are as follows: transthyretin subunit, apolipoprotein CIII0, apolipoprotein CIII1, apolipoprotein C1112 Match.
  • the method for diagnosing diabetes provides: (a) Digestion with trypsin yields polypeptides having molecular weights of about 1270, about 1370, about 1390, about 1520, about 2450, about 2640, and about 3140. Digestion with a molecular weight of about 13800 and Z or (b) trypsin yields a positive molecular weight of about 900, about 1200, about 1390, about 1710, about 1940, and about 2080. It also includes a method in which a protein having a molecular weight of about 8700-9700 is used as a marker substance and the amount in the blood is compared with a healthy value.
  • peptide mass fingerprinting is performed using the ProFound database, (a) is identified as transthyretin.
  • peptide mass fingerprinting is performed using the MS-Fit database
  • (b) is identified as apolipoprotein CIII.
  • One of the preferred embodiments of the method for diagnosing diabetes of the present invention is to capture a marker substance on a carrier and measure the concentration of the captured marker substance. That is, a substance having affinity for the marker substance is immobilized on the carrier, and the marker substance is captured on the carrier via the substance having the affinity. According to this embodiment, it is possible to reduce the influence of contaminants contained in the sample, and to measure the concentration of the marker substance with higher sensitivity and accuracy. Examples of “affinity” include antigen and antibody,
  • the present embodiment when immunoassay is used as a method for measuring a marker substance, it is preferable to use a carrier on which an antibody is immobilized. In this way, an immunoassay system using the antibody immobilized on the carrier as the primary antibody can be easily constructed. For example, prepare two types of antibodies that are specific to the marker substance and have different epitopes, one is immobilized on the carrier as the primary antibody, and the other is enzyme-labeled as the secondary antibody to construct a sandwich EIA system be able to. In addition, it is possible to construct an ImnoAtsuy system using the binding prevention method or the competition method. Furthermore, when a substrate is used as a carrier, immunoassay using an antibody chip is possible. According to the antibody chip, the concentration of a plurality of marker substances can be measured simultaneously, and rapid measurement is possible.
  • the marker substance when mass spectrometry is used in the marker substance measurement method in the present embodiment, the marker substance can be captured on a carrier by ion binding or hydrophobic interaction in addition to the antibody. Ion binding and hydrophobic interaction can also capture substances other than marker substances with specificities similar to those of bioaffinity such as antigens and antibodies, but according to mass spectrometry, the mass spectrometer spectrum reflects the molecular weight. Since it is quantified, there is no problem.
  • the concentration of the marker substance can be measured more accurately.
  • An exchange substrate and a metal ion substrate are preferably used.
  • the ion exchanger When the marker substance is captured on the carrier by ionic bonding, the ion exchanger is immobilized on the carrier.
  • an anion exchanger or a cation exchanger can be used as the ion exchanger, and moreover, Sarako, strong anion exchanger, weak anion exchanger, strong cation exchanger, weak cation exchanger.
  • Any ion exchanger can be used.
  • weak anion exchangers such as dimethylaminoethyl (DE) and jetylaminoethyl (DEAE) What has an anion exchange group is mentioned.
  • strong anion exchangers include quaternary ammonia (trimethylaminomethyl) (QA), quaternary aminoethyl (jetyl, mono-2-hydroxybutylaminoethyl) (QAE), and quaternary ammonia. And those having a strong anion exchange group such as -um (trimethylammonium) (QMA).
  • weak cation exchangers include those having weak cation exchange groups such as carboxymethyl (CM). Further, examples of the strong cation exchanger include those having a strong cation exchange group such as sulfopropyl (SP).
  • a substance having a hydrophobic group is immobilized on the carrier.
  • the hydrophobic group include a C4 to C20 alkyl group and a phenyl group.
  • metal ions such as Cu2 +, Zn2 +, Ni2 +, Ca2 +, Co2 +, Mg2 + are immobilized.
  • the carrier used in the present embodiment known ones such as beads, microtiter plates, and resin can be used.
  • beads and microtiter plates have also been used in conventional immunoassays, making it easy to build a measurement system.
  • a carrier having a planar portion such as a substrate can also be used.
  • An example is a carrier in which a chip is used as a substrate and an antibody specific for a marker substance is immobilized in spots on a plurality of spots on the surface.
  • serum or plasma prepared from the blood force it is preferable to use blood collected from a subject as a specimen and serum or plasma prepared from the blood force as a test material.
  • Serum or plasma can be prepared by a known method such as centrifugation.
  • FIG. 1 is a flow chart showing the procedure of the method for diagnosing diabetes of the present invention using a multimarker system. According to the method of the flowchart in FIG. 1, firstly, a primary determination is made using the concentration of transthyretin in blood as an index. If the concentration of transthyretin is higher than the normal value, it is determined as diabetes.
  • the concentration of transthyretin is below the normal value If this is the case, a secondary determination is made using the concentration of apolipoprotein CIII2 in the blood as an index. If the concentration of apolipoprotein CIII2 is higher than the normal value, it is determined as diabetes. On the other hand, if the concentration of apolipoprotein CIII2 is below the normal value, a third determination is made using the concentration of apolipoprotein cmi in the blood as an index. If the concentration of the apolipoprotein cmi is below the normal value, it is determined as normal (not diabetic).
  • a quaternary determination is made using the concentration of apolipoprotein cmo in the blood as an index. And when the density
  • FIG. 2 is a flowchart showing the procedure of the method for diagnosing diabetes of the present invention using another multimarker system.
  • a primary determination is made using the concentration of serum albumin in blood as an index. If the serum albumin concentration is equal to or higher than the normal value, it is determined as normal (not diabetic). On the other hand, if the serum albumin concentration is lower than the normal value, a secondary determination is made using the concentration of apolipoprotein CIII2 in the blood as an index. If the concentration of apolipoprotein CIII2 is higher than the normal value, it is determined as diabetes.
  • a third determination is made using the concentration of apolipoprotein cmi in the blood as an index. If the apolipoprotein cmi concentration is below the normal level, it is determined as normal (not diabetic). On the other hand, if the concentration of apolipoprotein cmi is higher than the normal value, a quaternary determination is made using the concentration of apolipoprotein cmo in the blood as an index. If the concentration of apolipoprotein cmo is higher than the normal value, it is determined as diabetes. On the other hand, if the concentration of apolipoprotein cmo is below normal, it is determined as normal (not diabetic).
  • transthyretin, apolipoprotein CIII, and serum albumin used as diabetes markers in the present invention are combined with conventionally known clinical markers such as HbAlc and CPR to achieve multi-function. It is possible to build a marker system.
  • diabetes can be diagnosed with high accuracy. Furthermore, it is also suitable for detection of a stage before the onset of diabetes, that is, diagnosis of a diabetic reserve army, which is difficult with a conventional method for diagnosing diabetes. In addition, according to the multi-marker system, it is possible to detect the diabetes reserve army only by detecting diabetes and monitor the improvement state of diabetes with high accuracy.
  • the diabetes diagnosis kit of the present invention comprises an antibody specific for a marker substance such as transthyretin.
  • the antibody contained in the kit may be a single reagent, or may be immobilized in advance on a carrier.
  • the shape may be a solution or a lyophilized product.
  • a plurality of antibodies may be included.
  • a labeled antibody used in Immunase may be included as a secondary antibody.
  • the kit for diagnosing diabetes of the present invention may contain other reagents. For example, if it is a kit for performing EIA, a carrier such as beads, a blocking solution, a buffer solution such as PBS, a chromogenic substrate, etc. May be included.
  • the disease diagnosis method of the present invention compares the concentration of at least one of the following marker substances (a) to (n) in the body fluid of a subject with a healthy value, and determines the presence or absence of diabetes or the risk of future onset. Judgment.
  • (m) weak cation exchange at pH 4.0 A protein that binds to the body and produces an ion peak with a mass to charge ratio of approximately 12800 when subjected to mass spectrometry,
  • All of these marker substances are mainly proteins present in blood. If the subject develops diabetes or has a high risk of developing diabetes in the future, the marker substances in body fluids (a), (b), (c), (d), (e) , (F), (g), (h), and (i) concentrations are higher, and marker substances, (k), (1), (m), and (n) concentrations are lower.
  • the Hereinafter, the group consisting of marker substances (a), (b), (c), (d), (e), (f), (g), (h), and (i) is referred to as “Group 1”, and the marker substance
  • the loop consisting of (j), (k), (1), (m) and (n) may be referred to as “Group 2”.
  • the healthy value used in the disease diagnosis method of the present invention is, for example, in the body fluid of the marker substances (a) to (n) in a healthy person who has been diagnosed as having developed diabetes! Concentration data can be collected and set based on that concentration value. When determining the future risk of developing diabetes, a healthy value can be set based on the concentration value in the healthy person. It is also possible to set multiple healthy values in stages and quantitatively determine the presence or absence of diabetes or the risk of future onset.
  • blood is preferably used.
  • serum or plasma body fluid component
  • Serum or plasma can be prepared from blood by a known method such as centrifugation.
  • the present invention provides a method for evaluating a substance, in which an animal that develops diabetes or an animal that has a high risk of developing the disease ingests a test substance and a marker in the body fluid of the animal Compares the concentration of at least one substance (for example, 14 types (a) to (n)) with a reference value, and evaluates the effect of the test substance on improving diabetes or reducing the risk of future onset. is there.
  • a marker substance is used as an index instead of using blood glucose as a direct index, a state before an increase in blood glucose level in an animal can be captured.
  • “Animals” include humans in addition to animals such as rats.
  • the body fluid or body fluid component is contacted with a carrier in which a substance having affinity for the marker substance is immobilized.
  • the marker substance in the body fluid is captured on the carrier, and the concentration of the marker substance in the body fluid is calculated based on the amount of the captured marker substance (claim 10), the carrier is a planar portion
  • the substance having affinity for the marker substance is configured to be fixed to a part of the planar portion, and the substance having affinity for the marker substance is an ion exchanger, metal chelate or With antibodies A configuration is recommended.
  • an animal that develops diabetes or an animal that has a high future risk of developing is ingested with a test substance, and the marker substances (a) to (! 1) in the animal are ingested. At least one concentration is compared with a reference value to evaluate the effect of the test substance on improving diabetes or reducing the risk of future onset.
  • the concentration of the marker substance belonging to Group 1 in the body fluid is lower, and the concentration of the marker substance belonging to Group 2 is lower. Indicates a higher value.
  • the reference value does not have an effect of improving diabetes or reducing the risk of developing future in animals that develop diabetes!
  • the concentration of the marker substance in the body fluid of the animal when a known substance is ingested is used. That is, if an animal that has developed diabetes or an animal that has a high risk of developing in the future is ingested with a known substance that does not have an effect of improving diabetes or a risk of reducing the risk of developing future disease, the marker substance in the body fluid
  • the concentration of is an “abnormal value”.
  • the value (measured value) in the animal ingested with the test substance is compared with the reference value (abnormal value), and if the measured value is significantly different from the reference value and is on the normal side (normal side)
  • the test substance can be evaluated as having an effect of improving diabetes or reducing the risk of future onset.
  • the marker substance belonging to Group 1 is used as an index
  • the measured value is significantly lower than the reference value
  • the marker substance belonging to Group 2 when the marker substance belonging to Group 2 is used as an index
  • the measured value is When the test substance is significantly higher than the reference value, it can be evaluated that the test substance has an effect of improving diabetes or a risk of reducing future risk.
  • a value (normal value; negative reference) in an animal or animal that has a low risk of developing diabetes can be added to the reference value.
  • Known substances that have no effect of improving diabetes or reducing the risk of future onset in animals Three groups are established: a group to be ingested (a group that exhibits abnormal values), and (3) a group in which the test substance is ingested by an animal that has developed diabetes or a high risk of developing diabetes. Is raised. Then, the marker substance in the body fluid of each animal is measured and the measured values are compared. At this time, there is a significant difference between (1) and (2), there is a significant difference between (3) and (2), and (3) is closer to the normal side (close to (1) than (2) If the test substance is maintained on the normal side, it can be evaluated that the test substance has an effect of improving diabetes or reducing the risk of developing the disease in the future. In other words, if the test substance has an effect of improving diabetes or reducing the risk of future onset, the blood glucose level is maintained at the normal level in (3) and the concentration of the marker substance is close to the normal level (1) Takes a value.
  • (4) a group in which an animal that has developed diabetes or an animal that has a high future risk of taking a known substance that has an effect of improving diabetes or reducing the risk of developing future Values in animals (positive controls) can also be added.
  • the group of (4) above is set up and raised.
  • the test substance can be evaluated as having an effect of improving diabetes or reducing the risk of future onset.
  • it can be said that such a test substance exhibits the same behavior as the known substance adopted in (4) and has the same action.
  • the above-mentioned "animal that develops diabetes! /, Or an animal that has a high risk of developing diabetes” can be realized, for example, by using an animal that necessarily genetically develops diabetes. More specifically, for example, OLETF (Otsuka Long-Evans Tokushima Fatty) rats supplied by Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd. can be used. OLETF rats are model rats that spontaneously develop type 2 diabetes with obesity. In males, almost all cases are diagnosed with diabetes by OGTT at 25 weeks of age.
  • an animal that does not develop diabetes or an animal that has a low risk of developing diabetes can be realized, for example, by using a model animal that does not genetically develop diabetes at all. More specifically, for example, LETO (Long-Evans Tokushima Otsuka) rats supplied from Tokushima Laboratory, Otsuka Pharmaceutical Co., Ltd. can be used. LETO rats are control rats that never develop diabetes and are genetically OLET It is closely related to F-Rad.
  • the animal used in the method for evaluating a substance of the present invention is not particularly limited, and examples thereof include mice, rats, rabbits, pigs, and the like. In particular, since rats and mice can be easily bred, they are preferably used in the evaluation method of the present invention. There are no particular limitations on the method of raising the animal. For example, the animal can be fed freely for about 3 to 20 days. Furthermore, humans can also be used as animals. When humans are used, substances will be evaluated based on the results of clinical trials.
  • Blood is preferably used as an animal body fluid used in the method for evaluating a substance of this aspect.
  • serum or plasma body fluid component
  • Serum or plasma can be prepared by a known method such as centrifugation.
  • test substance in the method for evaluating a substance of the present invention examples include food materials and drug substances.
  • food materials when food materials are to be evaluated, it can be used to develop functional foods.
  • an evaluation kit can be constructed by collecting necessary reagents.
  • the evaluation kit include those containing a carrier on which a substance having affinity for a marker substance is immobilized.
  • a carrier on which a weak cation exchanger such as CM, a metal chelate such as copper ion, or a substrate on which an antibody against a marker substance is immobilized SELDI-TO F-MS or antibody Immunization with a chip can be performed easily.
  • the kit may contain other reagents such as standard substances and various pretreatment buffers.
  • the substance screening method of the present invention evaluates a test substance by the substance evaluation method of the present invention, and screens for a substance having an effect of improving diabetes or reducing the risk of developing the future.
  • the same embodiment as the above-described method for evaluating substances of the present invention can be employed.
  • the present invention also evaluates a test substance by the method for evaluating a substance described in the present invention.
  • a screening method for a substance characterized by screening a substance having an effect of ameliorating a disease or an effect of reducing the risk of developing the future.
  • the present invention relates to a method for screening a substance, and compares at least one concentration of a marker substance (for example, 14 species (a) to (n)) in an animal body fluid with a reference value to improve diabetes.
  • a marker substance for example, 14 species (a) to (n)
  • This is to screen for substances that have an effect or reduce the risk of future onset.
  • blood glucose is not directly used as an index, but another marker substance is used as an index, so that it is possible to capture a state before an increase in blood glucose level in an animal.
  • substances having an effect of reducing the risk of developing future diabetes can be screened.
  • the test substance is a food material
  • the present invention also provides a substance obtained by such a screening method.
  • Each fraction was subjected to SELDI-TOF-MS using a protein chip to exhaustively search for proteins specific to the serum of diabetic patients.
  • protein chips metal ions (Cu2 +), weak cation exchangers (CM), strong anion exchangers (Q), and reversed-phase (C16 alkyl chains). I examined it.
  • Two types of energy-absorbing substances (EAM) were studied: a-cyanose 4-hydroxycacin acid (CHC A) and sinapinic acid (SPA).
  • CHC A a-cyanose 4-hydroxycacin acid
  • SPA sinapinic acid
  • a number of peaks were detected depending on combinations of protein chip type, fraction type, chip washing conditions (pH), EAM type, and the like. From these peaks, we searched for peaks with significantly different intensities between diabetics and healthy individuals.
  • Mass / charge it (m / z) force S 13867, 14049, 13885 using a protein chip with a weak cation exchanger fixed, and fraction 4 with a wash pH of 7.0 Five peaks at 14087 and 13761 were detected. In addition, using a protein chip with a weak cation exchanger immobilized, and a wash pH of 4.0 for fraction 5, a peak of mZz force 3885 was detected. From these six peaks, it was suggested that a candidate protein (hereinafter referred to as “candidate protein (1)”) exists in the vicinity of a molecular weight range of 13800 to 14100.
  • FIGS. 3 (a) to 3 (c) show an example of a peak having an mZz of 13 867.
  • Fig. 3 (a) is a graph plotting peak intensities for diabetics and healthy individuals, and the horizontal line is the cutoff value.
  • Fig. 3 (b) is a graph showing the results of Fig. 3 (a) in terms of maximum, minimum, median and cut-off values.
  • Fig. 3 (c) shows the ROC curve. The closer the ROC area is to 1, the higher the accuracy of the measurement system (the closer the curve is to the upper left)! Create a similar graph (not shown) for the other five peaks. It was. Table 2 below summarizes the P value, ROC area, chip used, chip cleaning conditions, fractions, and EAM used for each peak.
  • Candidate protein (1) was purified from the serum of diabetic patients by the following procedure. First, 75 L of a denaturing buffer (9 M urea, 2% CHAPS, 50 mM Tris-HCl (pH 9.0)) was added to 50 L of serum of a diabetic patient and treated at 4 ° C for 20 minutes. In addition, wash Z-binding buffer (50 mM phosphate buffer (pH 7.0) containing lOOmM NaCl) 1.5 mL of the diluted Z-buffer, and then equilibrated with wash Z-binding buffer, Q Ceramic HyperD FS pin Column (Biosepla Company). The mixture was stirred at 4 ° C for 30 minutes, and then washed twice with 500 L of washing / binding knife.
  • a denaturing buffer 9 M urea, 2% CHAPS, 50 mM Tris-HCl (pH 9.0)
  • wash Z-binding buffer 50 mM phosphate buffer (pH 7.0) containing lOOmM Na
  • fractionation was performed by sequentially eluting with 100 L of 5 kinds of 50 mM phosphate buffer (pH 7.0) containing 125 mM, 150 mM, 175 mM, 200 mM, or 250 mM NaCl.
  • 50 mM phosphate buffer pH 7.0
  • a peak with a molecular weight of about 13800-14100 similar to that of the candidate protein (1) was found in the fraction eluted with a buffer containing 175 mM, 200 mM, and 250 mM NaCl. was detected. All albumin was eluted in the washing step before elution, and the candidate protein (1) and albumin were completely separated under these conditions.
  • Fractions with NaCl concentrations of 175 mM, 200 mM, and 250 mM were mixed (90 / z LX 3). Concentrate the mixed fractions with VivaSpin 5000 Cut Off (Sartorius), and add 10 volumes of 50 mM phosphate buffer (pH 7.0) to concentrate to a final volume of 50 L. I changed the koffer. Next, the concentrated sample was subjected to SDS-PAGE with a gel concentration of 16%, and the gel was stained with Coomassie Brilliant Blue (CBB). As a result, a target band was detected at a molecular weight of about 13800.
  • CBB Coomassie Brilliant Blue
  • the molecular weight of the conventionally known transthyretin subunit is 13890 and the isoelectric point is 5.3, whereas the molecular weight of the isolated protein is about 13800, and the expected isoelectric point is 5.3.
  • the physico-chemical properties of the two are almost the same.
  • transthyretin is known to be a tetramer consisting of four identical subunits, according to the results of this example, transthyretin is not in the form of a tetramer. Detected by subunit alone.
  • Example 2
  • Example 2 In the same manner as in Example 1, another candidate peak was searched. As a result, two peaks with m / z of 9279 and 9705 were detected when a protein chip fixed with a weak cation exchanger was used and the washing pH of fraction 6 was 4.0. In addition, when a protein chip on which a weak cation exchanger was immobilized and a washing pH of 4.0 was set to 4.0, two peaks with mZz of 9 285 and 9415 were detected. In addition, three peaks of mZz forces 9289, 9638, and 9712 were detected using a protein chip with a weak cation exchanger immobilized and a washing pH of 7.0 for fraction 6.
  • Figs. 4 (a) to 4 (c) show examples of mZz peaks at 8690 !.
  • Fig. 4 (a) is a graph plotting peak intensities for diabetics and healthy individuals, and Fig. 4 (b) shows the results of Fig. 4 (a) with the maximum, minimum, median, and The graph shows the cutoff value, and Fig. 4 (c) shows the ROC curve. Similar graphs (not shown) were prepared for the other 10 peaks. Table 3 below summarizes the P value, ROC area, chip used, chip cleaning conditions, fractions, and EAM used for each peak.
  • Candidate protein (2) was purified from the serum of diabetic patients by the following procedure. First, 75 ⁇ L of denaturing buffer was added to 50 ⁇ L of serum of diabetic patients and treated at 4 ° C. for 20 minutes. Furthermore, after washing and diluting 1.5 mL of washing / binding buffer (50 mM phosphate buffer (pH 6.0)), it was applied to a Q Ceramic HyperD F Spin Column equilibrated with washing Z binding buffer. The mixture was stirred at 4 ° C for 30 minutes, and then washed twice with 500 L of washing Z-binding buffer. Next, contain 50 mM, 150 mM, or 250 mM NaCl.
  • washing / binding buffer 50 mM phosphate buffer (pH 6.0)
  • the target band purified by SDS-PAGE was digested in gel with a 0.02 ⁇ & / ⁇ L trypsin solution (dissolved in 25 mM ammonium bicarbonate (pH 8.0)).
  • trypsin solution dissolved in 25 mM ammonium bicarbonate (pH 8.0)
  • MALDI-MSZMS analysis was performed on the extinguished sample, at least five Pitaka S were detected, and their molecular weights were “898”, “1197”, “1717”, “1939”, “2076” ”Was calculated. Based on these data, the MS-Fit database was searched for known proteins and peptide mass fingerprinting was performed.
  • apolipoprotein cmo Three apolipoproteins cni were identified: apolipoprotein cmo, apolipoprotein CIII1, and apolipoprotein CIII2.
  • the molecular weights of apolipoprotein CIII0, apolipoprotein Cini, and apolipoprotein CIII2 that are conventionally known are 87 65, 9421, and 9713, respectively, while the isoelectric points are 4.95, 4.80, and 4.65, respectively.
  • the molecular weights of the three proteins isolated this time were 8690, 9415, and 9712, respectively, and the expected isoelectric points were all in the range of 4.5 to 5.0.
  • Serum from a diabetic patient was subjected to two-dimensional electrophoresis with IEF in the first dimension (horizontal direction) and SDS-PAGE in the second dimension (vertical direction).
  • the molecular weight was 6.5 to 14.4 kDa and the isoelectric point ( pi)
  • Three bands A, B, and C were detected around 5 (Fig. 5). These bands were not detected in the serum of healthy individuals.
  • SELDI-TOF-MS the molecular weights of A, B, and C coincided with the molecular weights of apolipoprotein CIII2, apolipoprotein cmi, and apolipoprotein cnio, respectively. This result coincided with the search result of the candidate protein (2) using the above protein chip.
  • Candidate peak search (3) Further candidate peaks were searched in the same manner as in Example 1. As a result, two peaks of mZz force 66418 and 66449 were detected when a protein chip fixed with a weak cation exchanger was used and the washing pH of fraction 3 was 7.0. In addition, when a protein chip with a weak cation exchanger fixed thereto was used and the washing pH was set to 4.0 for fraction 5, a peak with m Zz of 66449 was detected. In addition, using a protein chip with a weak cation exchanger fixed, and a washing pH of 7.0 for fraction 6, a peak of mZz force S66572 was detected.
  • candidate protein (3) was a candidate for a molecular weight in the range of 66000-67000.
  • This molecular weight value was very close to the known human serum albumin molecular weight (66439) value, and a peak almost identical to the molecular weight of human serum albumin with m Zz of 66449 was detected. 3) was identified as serum albumin.
  • Fig. 6 (a) to (c) shows an example of a peak with mZz of 66216.
  • Fig. 6 (a) is a graph plotting peak intensities for diabetic patients and healthy individuals, and Fig. 6 (b) shows the results of Fig. 6 (a) with the maximum, minimum, median, and cut values. This graph shows the off value, and Fig. 6 (c) shows the ROC curve. Since this peak shows a lower value in diabetic patients, the ROC curve in Fig.
  • a diabetes detection kit (1) having the following constitution was constructed.
  • This kit includes a substrate on which an antibody is immobilized.
  • the kit captures a marker substance on the substrate and measures transthyretin, apolipoprotein cm, and serum albumin in a sandwich EIA system. Detection is performed with fluorescently labeled streptavidin.
  • Apolipoprotein CHI standard product (lyophilized product)
  • Anti-human serum albumin monoclonal antibody immobilized glass substrate
  • a diabetes detection kit (2) having the following constitution was constructed. This kit is for measuring transthyretin, apolipoprotein cm, and serum albumin by sandwich EIA using a microtiter plate.
  • Apolipoprotein cm standard product (lyophilized product)
  • Anti-human serum albumin monoclonal antibody plate (96 holes)
  • OLETF rats were prepared as model rats with spontaneous onset of type 2 diabetes, and LETO rats were prepared as rats that did not develop type 2 diabetes of the same strain (genetically related) as the model rats.
  • OLE TF rats and LETO rats were also provided by Tokushima Laboratories, Otsuka Pharmaceutical Co., Ltd.
  • a group of LETO rats (Group 1) and a group of OLETF rats (Group 2) were established and each rat was raised.
  • CRF-1 Oriental Bioscience
  • Each group also started testing at 5 weeks of age and was raised until 50 or 62 weeks. 5 (at start of breeding), 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, and 49 at the age of each week [Do this OGTT!
  • Denaturation buffer (9% urea, 2% CHAPS, 50 mM Tris-HCl (pH9.0)) 30 / z L was added to each serum sample 20; .
  • each pretreated serum sample was applied to a strong anion exchange resin column (Q Ceramic Hyper D, Pyosepura).
  • a pH 9.0 buffer 50 mM Tris—HC1 (pH 9.0), 0.1% (WZV) 1—o—N-octyl- ⁇ -D-darcobilanoside (hereinafter referred to as “OGPJ”)).
  • pH 7.0 buffer 50 mM HEPES—NaOH (pH 7.0), 0.1% (wZv) OGP) ⁇ pH 5.0 buffer (lOOmM sodium oxalate (pH 5.0), 0.1% (wZv ) OGP), pH 4.0 buffer (lOOmM sodium acetate (pH 4.0), 0.1% (w / v) OGP) ⁇ pH 3.0 buffer (50 mM sodium citrate (pH 3.0), 0 l% (w / v) OGP), and organic solvent (33.3% isopropyl alcohol, 16.7% acetonitrile, 0.1% trifluoroacetic acid mixture) elute sequentially at 200 / z L each, fraction 1 (elute at ⁇ 9.0) , Pass-through), fraction 2 (eluted at pH 7.0), fraction 3 (eluted at pH 5.0), fraction 4 (eluted at pH 4.0), fraction 5 (eluted at pH 3.0), fraction Six crude fractions of 6 (organic solvent) were obtained
  • Each of the obtained fractions was diluted 10-fold with a pH 4.0 protein chip binding buffer (lOOmM sodium acetate) and then added to a cation exchange chip CM10 (Cyphergen).
  • CM10 cation exchange chip
  • 10 L of each of the obtained fractions was diluted 10-fold with pH 7.0 protein chip binding buffer (lOOmM phosphoric acid, 0.5 M NaCl), and then added with copper modified chip IMAC30 (Cyphergen) did.
  • Each protein chip was washed 3 times with each binding buffer and then once with deionized water and dried.
  • FIG. 7 shows a box plot when the peak intensity of this peak at 21 weeks of age is plotted for each group.
  • the top and bottom edges of the basket are the maximum and minimum values, respectively
  • the top and bottom sides of the box are the third quartile (75th percentile) and the first quartile (25th percentile), respectively
  • the lines in the box are The median value (the same applies to the following figures). That is, this peak showed a low value in the first group and a high value in the second group.
  • the marker substance (a) is also present in human blood, it is possible to determine the onset of diabetes or the risk of future development using the concentration of the marker substance (a) in the blood as an index. It was shown that it can be done.
  • the test substance evaluates the effect of improving diabetes or reducing the risk of future onset, and It was shown that screening of new substances can be performed. For example, the same animal experiment using a desired test substance is performed to prepare a serum sample, and when SELDI-TOF-MS is performed in the same procedure, a peak with a mass-Z charge ratio of about 7040 is obtained. When the concentration of the protein that produces the above is maintained at a normal value, the test substance can be evaluated as having an effect of improving diabetes or reducing the risk of developing the future.
  • the test substance evaluates the effect of improving diabetes or reducing the risk of future onset, And it has been shown that such substances can be screened. For example, when a serum sample is prepared by performing the same animal experiment using a desired test substance and SELDI-TOF-MS is performed in the same procedure, a peak with a mass-Z charge ratio of about 8330 is obtained. When the concentration of the resulting protein is maintained at a normal value, the test substance can be evaluated as having an effect of improving diabetes or reducing the risk of developing the future.
  • the marker substance (c) when the marker substance (c) is also present in human blood, the presence or absence or future risk of developing diabetes is determined using the marker substance (c) concentration in the blood as an index. It was shown that Furthermore, using the concentration of the marker substance (c) in the blood of the animal ingested as the test substance as an index, the test substance evaluates the effect of improving diabetes or reducing the risk of future onset, And it has been shown that such substances can be screened. For example, when a similar animal experiment is performed using a desired test substance to prepare a serum sample and SELDI-TOF-MS is performed in the same procedure, a peak with a mass-Z charge ratio of about 8530 is obtained. When the concentration of the resulting protein is maintained at a normal value, it can be evaluated that the test substance has an effect of improving diabetes or reducing the risk of developing the future.
  • the concentration of the marker substance (d) in the blood is used as an index to detect diabetes. It has been shown that the presence of onset or the risk of future onset can be determined. Furthermore, using the concentration of the marker substance (d) in the blood of the animal ingested as the test substance as an index, the test substance evaluates the effect of improving diabetes or reducing the risk of developing the future, and such It has been shown that screening of substances can be performed. For example, when a similar animal experiment is performed using a desired test substance to prepare a serum sample, and SELDI-TOF-MS is performed in the same procedure, a peak with a mass-Z charge ratio of about 9060 is obtained. When the concentration of the resulting protein is maintained at a normal value, the test substance can be evaluated as having an effect of improving diabetes or reducing the risk of developing the future.
  • the marker substance (e) when the marker substance (e) is also present in human blood, the presence or absence or future risk of developing diabetes is determined using the marker substance (e) concentration in the blood as an index. It was shown that In addition, using the concentration of the marker substance (e) in the blood of the animal that ingested the test substance as an index, evaluate the effect of the test substance on improving diabetes or reducing the risk of future onset. It has been shown that screening of such substances can be performed. For example, when a similar animal experiment is performed using a desired test substance to prepare a serum sample and SELDI-TOF-MS is performed in the same procedure, a peak with a mass-to-charge ratio of about 9260 is generated. When the protein concentration is maintained at a normal value, the test substance can be evaluated as having an effect of improving diabetes or reducing the risk of developing the future.
  • Corrected form (Rule 91) A box plot when the peak strength is plotted for each group is shown. That is, this peak showed a low value in the first group and a high value in the second group. From 2 and above, a protein that produces a peak with a mass / charge ratio of about 9450 when subjected to SELDI-TOF-MS (marker substance (f)) is specific to rats with diabetes or high risk of development in the future. It was found that the substance can be a marker for the disease. As a result, when a single marker substance (f) is also present in human blood, it is possible to determine the presence or future risk of developing diabetes using the marker substance (f) concentration in the blood as an index. It was shown that we can do it.
  • the test substance evaluates the effect of improving diabetes or reducing the risk of developing the future, and such It has been shown that screening of substances can be performed. For example, when a similar animal experiment is performed using the desired test substance to prepare a serum sample and SELDI-TOF-MS is performed in the same procedure, a peak with a mass-Z charge ratio of about 9450 is obtained. When the concentration of the resulting protein is maintained at a normal value, the test substance can be evaluated as having an effect of improving diabetes or reducing the risk of developing the future.
  • the marker substance (g) when the marker substance (g) is also present in human blood, the presence or absence of diabetes or the risk of developing it in the future is determined using the marker substance (g) concentration in the blood as an index. It was shown that In addition, using the concentration of the marker substance (g) in the blood of the animal ingested as an index, the test substance evaluates the effect of improving diabetes or reducing the risk of developing the future, and It has been shown that such substances can be screened.
  • test substance For example, a similar animal experiment is performed using a desired test substance to prepare a serum sample, When the SELDI-TOF-MS is performed in order and the concentration of the protein that produces a peak with a mass-Z charge ratio of approximately 13700 is maintained at a normal value, the test substance is effective in improving diabetes or developing in the future. It can be evaluated that it has a risk reduction effect.
  • the test substance evaluates the effect of improving diabetes or reducing the risk of developing the future, and such It has been shown that screening of substances can be performed. For example, when a similar animal experiment is performed using a desired test substance to prepare a serum sample, and a SELDI-TOF-MS is performed in the same procedure, a peak with a mass-Z charge ratio of about 76400 is obtained. When the concentration of the resulting protein is maintained at a normal value, the test substance can be evaluated as having an effect of improving diabetes or reducing the risk of developing the future.
  • the test substance evaluates the effect of improving diabetes or reducing the risk of future onset, and such It has been shown that screening of substances can be performed. For example, when a similar animal experiment is performed using the desired test substance to prepare a serum sample, and SELDI-TOF-MS is performed in the same procedure, a peak with a mass-Z charge ratio of about 79100 is obtained. When the concentration of the resulting protein is maintained at a normal value, the test substance can be evaluated as having an effect of improving diabetes or reducing the risk of developing the future.
  • the concentration of marker substance (j) in the blood as an index when the marker substance G) is also present in human blood. It has been shown . Furthermore, using the concentration of the marker substance (i) in the blood of the animal ingested as an index, the test substance evaluates the effect of improving diabetes or reducing the risk of future onset, and such It has been shown that screening of substances can be performed. For example, when a similar animal experiment is performed using the desired test substance to prepare a serum sample and SELDI-TOF-MS is performed in the same procedure, a peak with a mass-to-Z charge ratio of about 3500 is obtained. When the concentration of the resulting protein is maintained at a normal value, the test substance can be evaluated as having an effect of improving diabetes or reducing the risk of developing the future.
  • the marker substance (k) when the marker substance (k) is also present in human blood, it is possible to determine the presence or future risk of developing diabetes using the marker substance (k) concentration in the blood as an index. It has been shown. Furthermore, using the concentration of the marker substance (k) in the blood of the animal ingested as the test substance as an index, the test substance evaluates the effect of improving diabetes or reducing the risk of developing the future, and such It has been shown that screening of substances can be performed. For example, when a similar animal experiment is performed using a desired test substance to prepare a serum sample and SELDI-TOF-MS is performed in the same procedure, a peak with a mass-Z charge ratio of about 3560 is obtained. When the concentration of the resulting protein is maintained at a normal value, it can be evaluated that the test substance has an effect of improving diabetes or reducing the risk of developing the future.
  • a protein that produces a peak with a mass-to-Z charge ratio of about 4180 when subjected to SELDI-TOF-MS is specific to rats with diabetes or high risk of developing in the future. It was found that this substance can be a marker for the disease.
  • marker substance (1) when marker substance (1) is also present in human blood, it is possible to determine the onset of diabetes or the risk of future development using the concentration of marker substance (1) in the blood as an index. It has been shown. Furthermore, using the concentration of the marker substance (1) in the blood of the animal ingested as the test substance as an index, the test substance evaluates the effect of improving diabetes or reducing the risk of future onset, and such It has been shown that screening of substances can be performed. For example, the desired When a test sample is used to prepare a serum sample by performing the same animal experiment and SELDI-TOF-MS is performed in the same procedure, the concentration of the protein that produces a peak with a mass-to-charge ratio of about 4180 is obtained. When maintained at a normal value, the test substance can be evaluated as having an effect of improving diabetes or reducing the risk of developing the future.
  • a protein that produces a peak with a mass-to-Z charge ratio of about 12800 when subjected to SELDI-TOF-MS is specific to rats with diabetes or high risk of developing in the future. It was found that this substance can be a marker for the disease.
  • the presence of diabetes or the risk of future development can be determined using the marker substance (m) concentration in the blood as an index. It was shown that it can be done. Furthermore, using the concentration of the marker substance (m) in the blood of the animal ingested as an index, the test substance evaluates the effect of improving diabetes or reducing the risk of future onset, and It was shown that screening of new substances can be performed. For example, if a serum sample is prepared by performing similar animal experiments using the desired test substance and SELDI-TOF-MS is performed in the same procedure, a peak with a mass / charge ratio of approximately 12800 is obtained. When the concentration of the resulting protein is maintained at a normal value, the test substance can be evaluated as having an effect of improving diabetes or reducing the risk of developing the future.
  • FIG. 20 shows a box plot when the peak intensity of this peak at 21 weeks of age is plotted for each group. That is, this peak showed a high value in the first group and a low value in the second group.
  • Corrected form (Rule 91) It was found that it can be a marker for the disease. As a result, when a single marker substance (n) is also present in human blood, it is possible to determine the onset of diabetes or the risk of future development using the marker substance (n) concentration in the blood as an index. It was shown that it can be done. Furthermore, using the concentration of the marker substance (n) in the blood of the animal ingested as an index, the test substance evaluates the effect of improving diabetes or reducing the risk of future onset, and It was shown that screening of new substances can be performed.
  • Example 7 when a similar animal experiment is performed using the desired test substance to prepare a serum sample, and a SELDI TOF MS is performed in the same procedure, a peak with a mass Z charge specific force of about 65700 is generated.
  • the test substance can be evaluated as having an effect of improving diabetes or reducing the risk of developing the future.
  • Amersham HiTrapQ is a strong anion exchange column after diluting 5 times of 500 L of serum of diabetic patients and healthy individuals with 50 mM Tris-HCl (pH 7.0) and centrifuging at 20 kG, 4 ° C, lOmin. Fractionation was performed using 1 mL of HP. First, 5 CV washing was performed with 50 mM Tris-HCl (pH 7.0), and then 5 CV washing was performed with 50 mM Tris-HCl (pH 7.0) and 160 mM NaCl. Elution was performed at 2 CV using 50 mM Na-Acetate (pH 4.0).
  • the eluted sample was subjected to acetone precipitation with 5 volumes of acetone, and the resulting precipitate was mixed with 62.5 mM Tris-HCl (pH 6.8), 1% SDS, 20% glycerol, 0.005% BPB mixed solution 200 Dissolved in L to prepare a sample for SDS-PAGE.
  • TBS Tris-buffer saline
  • Anti-human Transthyretin antibody (rabbit IgG 200 g / mL) diluted 1000 times with TTBS (final concentration 0.2 ⁇ g / mL)
  • AP color development buffer Dilute 25x stock 25 times with ultra pure water to make AP color development buffer. 200 ⁇ L of AP color development reagent A, 200 against 20 mL of AP color development buffer Add ⁇ L of AP color development reagent B to make AP color solution.
  • the plate was immersed in TTBS and washed by shaking for 5 minutes x 3 times at room temperature.
  • FIG. 25 shows the tetrameric structure of TTR and the amino acid sequence of the monomer.
  • transthyretin usually has a tetrameric structure, and it is postulated that when it collapses, it becomes diabetic.
  • Figure 26 shows the three-dimensional structure and secondary structure of the human TTR a -domain. Derivatives can be analyzed by mass spectrometry using the typical post-translational modifications and mass changes in proteins and peptides shown in Table 1.
  • Rat Serum 750 / z L was diluted 5-fold with 50 mM Tris—HC1 (pH 6.0) and filtered using a Millipore Millex—HV (0.45 m) filter unit to obtain a sample.
  • Amersham HiTrapQ is a strong anion exchange column. Fractionation was performed using 1 mL of HP. First, wash with 5 mM V in 50 mM Tris—HCl (pH 6.0), then wash with 12 CV in 50 mM Tris—HCl (pH 6.0), 200 mM NaCl, and then with 50 mM Tris—HCl (pH 6.0). 5CV washing was performed. Elution was performed at 2 CV using 50 mM Na-Acetate (pH 3.0).
  • the eluted sample was subjected to acetone precipitation with 10 times the amount of acetone, and the resulting precipitate was mixed with 62.5 mM Tris-HCl (pH 6.8), 1% SDS, 20% glycerol, 0.005% BPB mixed solution. U-dissolved sample was used for SDS-PAGE.
  • Trypsin (20 i ug) is dissolved in 50 mM acetic acid (0.1 mL) to make a trypsin stock solution. Add tryptic solution (25 L) to ultrapure water (200 L), lOOmM bicarbonate (500 L), MeCNOO / z L) to make a trypsin solution.
  • Figure 27 shows a gel photograph of the identified band and analysis of the band by SELDI-TOF.
  • Fig. 28 shows a gel photograph of the identified band and analysis of the band by SELDI-TOF.
  • pH3.0 50 mM Na—Citrate Buffer pH 3.5-5.5: 50 mM Na— Acetate Buffer
  • FIG. 29 shows spots on two-dimensional electrophoresis that are considered to be spots of human polypoprotein CIII (0-2).
  • Fig. 30 shows the results of mass spectrometry of each spot.
  • Figure 31 shows the SELDI-MS results for each spot.
  • FIGS. 32 to 34 show the results of the examination of the optimum adsorption conditions.
  • Figure 32 shows the results of the CM10 study
  • Figure 33 shows the results of the Q10 study.
  • Figure 34 shows the results of the optimal condition study. From these results, it is clear that the obtained spot is a spot of human apolipoprotein cm (o-2).
  • This example shows that S-cysteylated transthyretin identified as described above shows a correlation even in the severity evaluation based on the hemoglobin (HbAlc) level. It was. HbAlc is currently used as the most reliable diabetes marker.
  • IMAC30 chelate metal (Cu) immobilization chip
  • Vertical axis S-cysteinyl measured with SELDI-TOF-MS Ion intensity of ated TTR; horizontal axis: C: control (healthy person), P: diabetic patient.
  • IMAC30 chelate metal (Cu) immobilization chip
  • Figure 36 shows the results.
  • Vertical axis ionic strength of S-cysteinylated TTR measured by SELDI—TOF—MS; horizontal axis: C: control (healthy person), P: diabetic patient.
  • Vertical axis ionic strength of S—cysteinylated TTR measured by SELDI—TOF—MS; horizontal axis: C: control (healthy), P: diabetic patients [0352]
  • FIG. 38 shows the actual measurement data of MZZ: 13, 863 in diabetic patients.
  • 8.3K predicted as a prophylactic (pre-) marker in the above example was identified as Apo CII.
  • the obtained sample was fractionated using Amersham HiTrapQ HP lmL which is a strong anion exchange column. First, wash with 5 mM CV with 50 mM Tris-HCl (pH 6.0), then wash with 50 mM Tris-HCl (pH 6.0), 200 mM NaCl (trowel 12 CV, then 50 mM Tris-HCl (pH 6. At 0), 5CV cleaning was performed.
  • the measurement was carried out twice washed ⁇ at 1% TFA line! / ,, matrix ⁇ or to ride 25 0/0 SPA 0. twice.
  • Trypsin (20 i ug) is dissolved in 50 mM acetic acid (0.1 mL) to make a trypsin stock solution. Add tryptic solution (25 L) to ultrapure water (200 L), lOOmM bicarbonate (500 L), MeCNOO / z L) to make a trypsin solution.
  • TBS Tris-buffer saline
  • AP coloring solution Dilute 25x stock 25 times with ultra pure water to make AP color development buffer. Add 200 L of AP color development reagent A and 200 ⁇ L of AP color development reagent B to 20 mL of AP color development buffer to make an AP color solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de diagnostic ou de prédiagnostic du diabète utilisé pour la détection ou la prévention du diabète et applicable à un système multimarqueur et un kit de diagnostic ou de prédiagnostic du diabète. Une ou plusieurs protéines sont sélectionnées dans le groupe constitué de transthyrétine, apolipoprotéine CII, apolipoprotéine CIII, sérum albumine et des substances relatives à ces éléments dans le sang et servent de substances de marquage du diabète. La concentration de chaque substance est comparée à une valeur normale et le diagnostic ou prédiagnostic du diabète est réalisé. On utilise un anticorps spécifique à la substance de marquage comme procédé d'essai de la concentration de la substance de marquage. On peut réaliser un essai par la capture de la substance de marquage dans un support. Au moyen du kit de diagnostic ou de prédiagnostic du diabète contenant un anticorps spécifique à la substance de marquage, on peut réaliser un diagnostic ou un prédiagnostic du diabète plus facilement et simplement.
PCT/JP2006/300115 2005-01-07 2006-01-06 Procede de prediction ou de diagnostic du diabete et kit de prediction ou diagnostic du diabete Ceased WO2006073195A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006550912A JPWO2006073195A1 (ja) 2005-01-07 2006-01-06 糖尿病の予知・診断方法および糖尿病予知・診断用キット

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2005002826 2005-01-07
JP2005-002826 2005-01-07
JP2005-327243 2005-11-11
JP2005327243 2005-11-11

Publications (1)

Publication Number Publication Date
WO2006073195A1 true WO2006073195A1 (fr) 2006-07-13

Family

ID=36647672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/300115 Ceased WO2006073195A1 (fr) 2005-01-07 2006-01-06 Procede de prediction ou de diagnostic du diabete et kit de prediction ou diagnostic du diabete

Country Status (2)

Country Link
JP (1) JPWO2006073195A1 (fr)
WO (1) WO2006073195A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055341A1 (fr) * 2005-11-11 2007-05-18 Biomarker Science Co., Ltd. Procede de pronostic/diagnostic differentiel du diabete et kit de pronostic/diagnostic du diabete
JP2008127364A (ja) * 2006-11-24 2008-06-05 Taiyo Kagaku Co Ltd マーカータンパク質発現制御剤
JP2009264932A (ja) * 2008-04-25 2009-11-12 Biomarker Science:Kk 運動機能の向上・維持・回復効果の評価方法及び評価用キット、並びに、物質のスクリーニング方法
JP2010019687A (ja) * 2008-07-10 2010-01-28 Biomarker Science:Kk 動脈硬化改善・予防効果の評価方法及び評価用キット、並びに、物質のスクリーニング方法
JP2010537157A (ja) * 2007-07-17 2010-12-02 メタボロン インコーポレイテッド 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法
CN102481319A (zh) * 2009-07-07 2012-05-30 英特琳斯克拜奥普洛博思有限公司 糖尿病前期和2型糖尿病中的载脂蛋白ciii
JP2013076703A (ja) * 2006-03-24 2013-04-25 Metanomics Gmbh 糖尿病の予測手段および予測方法
US20130225496A1 (en) * 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
US9944691B2 (en) 2012-03-16 2018-04-17 Albumedix A/S Albumin variants
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
US10501524B2 (en) 2012-11-08 2019-12-10 Albumedix Ltd Albumin variants
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
US10696732B2 (en) 2009-10-30 2020-06-30 Albumedix, Ltd Albumin variants
US10711050B2 (en) 2011-11-18 2020-07-14 Albumedix Ltd Variant serum albumin with improved half-life and other properties
CN112924687A (zh) * 2019-12-06 2021-06-08 中国科学院大连化学物理研究所 基于多肽组合标志物的糖尿病诊断试剂盒及其方法
CN112924689A (zh) * 2019-12-06 2021-06-08 中国科学院大连化学物理研究所 基于多肽组合标志物定量测定的糖尿病诊断试剂盒及其方法
US11555061B2 (en) 2009-02-11 2023-01-17 Albumedix, Ltd Albumin variants and conjugates

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000298131A (ja) * 1999-04-14 2000-10-24 Ryuzo Kawamori 前糖尿病状態の検出方法
WO2003032810A2 (fr) * 2001-10-15 2003-04-24 Genentech, Inc. Diagnostic et traitement de pathologies resistant a l'insuline
JP2003270241A (ja) * 2002-03-12 2003-09-25 Omron Corp 健康管理装置
WO2003102163A2 (fr) * 2002-06-04 2003-12-11 Metabolex, Inc. Procedes de diagnostic et de traitement du diabete et de la resistance a l'insuline
JP2004283086A (ja) * 2003-03-24 2004-10-14 Osaka Industrial Promotion Organization ２型糖尿病および動脈硬化のマーカー、およびこれを検出するためのプローブならびにプライマー

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000298131A (ja) * 1999-04-14 2000-10-24 Ryuzo Kawamori 前糖尿病状態の検出方法
WO2003032810A2 (fr) * 2001-10-15 2003-04-24 Genentech, Inc. Diagnostic et traitement de pathologies resistant a l'insuline
JP2003270241A (ja) * 2002-03-12 2003-09-25 Omron Corp 健康管理装置
WO2003102163A2 (fr) * 2002-06-04 2003-12-11 Metabolex, Inc. Procedes de diagnostic et de traitement du diabete et de la resistance a l'insuline
JP2004283086A (ja) * 2003-03-24 2004-10-14 Osaka Industrial Promotion Organization ２型糖尿病および動脈硬化のマーカー、およびこれを検出するためのプローブならびにプライマー

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOSHIKAWA T.: "Shirizu 'Nutrigenomics no Shokuhin Kino eno Oyo' -7-Nutrigenomics kara Proteomics eno Tenkai", ILSI, no. 80, 2004, pages 14 - 19 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055341A1 (fr) * 2005-11-11 2007-05-18 Biomarker Science Co., Ltd. Procede de pronostic/diagnostic differentiel du diabete et kit de pronostic/diagnostic du diabete
JP2013076703A (ja) * 2006-03-24 2013-04-25 Metanomics Gmbh 糖尿病の予測手段および予測方法
JP2008127364A (ja) * 2006-11-24 2008-06-05 Taiyo Kagaku Co Ltd マーカータンパク質発現制御剤
JP2010537157A (ja) * 2007-07-17 2010-12-02 メタボロン インコーポレイテッド 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法
JP2009264932A (ja) * 2008-04-25 2009-11-12 Biomarker Science:Kk 運動機能の向上・維持・回復効果の評価方法及び評価用キット、並びに、物質のスクリーニング方法
JP2010019687A (ja) * 2008-07-10 2010-01-28 Biomarker Science:Kk 動脈硬化改善・予防効果の評価方法及び評価用キット、並びに、物質のスクリーニング方法
US11555061B2 (en) 2009-02-11 2023-01-17 Albumedix, Ltd Albumin variants and conjugates
CN102481319A (zh) * 2009-07-07 2012-05-30 英特琳斯克拜奥普洛博思有限公司 糖尿病前期和2型糖尿病中的载脂蛋白ciii
EP2451466A4 (fr) * 2009-07-07 2012-12-12 Intrinsic Bioprobes Inc Apolipoprotéine ciii dans le prédiabète et le diabète de type 2
JP2012533066A (ja) * 2009-07-07 2012-12-20 イントリンジック バイオプローブズ，インコーポレイテッド 糖尿病前症及び２型糖尿病におけるアポリポタンパク質ｃｉｉｉ
US10696732B2 (en) 2009-10-30 2020-06-30 Albumedix, Ltd Albumin variants
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
US20130225496A1 (en) * 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
US10711050B2 (en) 2011-11-18 2020-07-14 Albumedix Ltd Variant serum albumin with improved half-life and other properties
US10329340B2 (en) 2012-03-16 2019-06-25 Albumedix Ltd Albumin variants
US9944691B2 (en) 2012-03-16 2018-04-17 Albumedix A/S Albumin variants
US10501524B2 (en) 2012-11-08 2019-12-10 Albumedix Ltd Albumin variants
US10934341B2 (en) 2012-11-08 2021-03-02 Albumedix, Ltd. Albumin variants
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
US12116400B2 (en) 2015-08-20 2024-10-15 Sartorius Albumedix Limited Albumin variants and conjugates
CN112924687A (zh) * 2019-12-06 2021-06-08 中国科学院大连化学物理研究所 基于多肽组合标志物的糖尿病诊断试剂盒及其方法
CN112924689A (zh) * 2019-12-06 2021-06-08 中国科学院大连化学物理研究所 基于多肽组合标志物定量测定的糖尿病诊断试剂盒及其方法

Also Published As

Publication number Publication date
JPWO2006073195A1 (ja) 2008-06-12

Similar Documents

Publication Publication Date Title
US20070292869A1 (en) Compositions and Methods for Analyzing Renal Cancer
WO2006073195A1 (fr) Procede de prediction ou de diagnostic du diabete et kit de prediction ou diagnostic du diabete
US20050048574A1 (en) Biomarkers for diagnosing rheumatoid arthritis
EP2121747A2 (fr) Nouvelles protéines isoformes et leur utilisation
JP2003284574A (ja) 核酸分子、ポリペプチド、ならびにアルツハイマー病の診断および処置を含むそれらの使用
EP2333552B1 (fr) Biomarqueurs inédits de la stéatose hépatique non alcoolique et méthodes de détection d'une stéatose hépatique non alcoolique au moyen dudit biomarqueur
JP2009515183A (ja) 新たなタンパク質アイソフォーム及びその使用
JP2005510575A (ja) アルツハイマー病を予測するｉｇ重鎖、ｉｇカッパ、ｉｇラムダバイオポリマーマーカー
WO2015025975A1 (fr) Méthode et trousse de détection d'un début ou d'un risque de début de néphropathie diabétique
WO2002046767A2 (fr) Molecules d'acide nucleique, polypeptides et utilisations associees, parmi lesquelles diagnostic et traitement de la maladie d'alzheimer
US20070264643A1 (en) Compositions and Methods Relating to CNS Lymphoma
JP5688829B2 (ja) 示差的な糖尿病の予知・診断方法および糖尿病予知・診断用キット
WO2006107078A1 (fr) Procede destine a evaluer l’efficacite du traitement par interferon et kit d’evaluation de celle-ci
US7026129B2 (en) IG lambda biopolymer markers predictive of Alzheimers disease
JP6004369B2 (ja) 糖尿病合併症マーカーとなり得る新規ｒａｇｅリガンド
JP2005510728A (ja) インスリン耐性を予測するタンパク質バイオポリマーマーカー
JP2005510731A (ja) Ｉｉ型糖尿病のスクリーニングのためのフィブリノゲンバイオポリマーマーカーおよびその使用
WO2006108051A2 (fr) Compositions et methodes pour le diagnostic et le traitement de la maladie d'alzheimer
JP2005523422A (ja) インスリン耐性を予測するタンパク質バイオポリマーマーカー
JP2005510718A (ja) Ｉｉ型糖尿病を予測する補体ｃ３前駆体バイオポリマーマーカー
JP2007278811A (ja) インターフェロン療法の有効性判定方法および判定用キットの改良
JP2005523420A (ja) アルツハイマー病を示す補体ｃ３前駆体バイオポリマーマーカー
JP2005523419A (ja) インスリン耐性を示すフィブロネクチンおよびフィブリノゲンバイオポリマーマーカー
JP2005525535A (ja) インスリン耐性を示すマクログロブリンバイオポリマーマーカー
JP2005510727A (ja) アルツハイマー病を予測するｈｐおよびアポリポタンパク質バイオポリマーマーカー

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006550912

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06711485

Country of ref document: EP

Kind code of ref document: A1

WWW Wipo information: withdrawn in national office

Ref document number: 6711485

Country of ref document: EP